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Dry eye disease (DED) affects more than 10 million individuals in the United States. DED 
originates from disruption of the immunological homeostasis of the lacrimal functional unit 
(LFU). This disruption stems from persistent infiltration of pro-inflammatory effector CD4+ T 
lymphocytes (Teff) into the LFU, and reduced numbers and/or function of immunosuppressive 
regulatory T cells (Tregs). Current clinical treatments block pro-inflammatory signaling but do 
not address the underlying immunological imbalance in DED. Notably, in a healthy state, the 
body utilizes sophisticated regulatory mechanisms that include Tregs to promote immunological 
balance. Indeed, ex vivo expanded Tregs, adoptively transferred into mice with induced DED, 
effectively ameliorates disease symptoms. Using living Tregs to dynamically and responsively 
manipulate the local immunological milieu to treat DED would represent a departure from 
traditional drug-based treatments. Although Treg cell therapy is an extremely promising 
treatment for DED, ex vivo Treg expansion has significant limitations, such as regulatory 
hurdles, Treg plasticity, and high costs. For these reasons, we developed several acellular 
approaches that utilize biodegradable microspheres composed of poly(lactic-co-glycolic acid) to 
release different factors capable of recruiting endogenous Tregs and/or inducing local Tregs in 
the ocular tissue to restore immunological homeostasis. To this end, our data suggest that 
controlled release systems can generate and sustain a biological gradient of the Treg-preferential 
chemoattractant, CCL22, recruiting endogenous Tregs. In turn, these “Treg-recruiting 
formulations” reduce the symptoms of DED when placed locally in the lacrimal gland in a 
 
TREG RECRUITMENT/INDUCTION FOR THE PREVENTION OF AN 
EXPERIMENTAL INFLAMMATORY MODEL OF DRY EYE DISEASE 
 
Michelle Lynn Ratay, Ph.D. 
University of Pittsburgh, 2017
 
 v 
Concanavalin A-induced murine model of DED. Moreover, the local delivery of TGF-β, IL-2, 
and Rapamycin from similar controlled release systems induces local differentiation of naïve 
CD4+ T cells into FoxP3+ Treg, which in turn, prevents DED symptoms such as loss of tear 
production, maintenance of goblet cell density, and ocular surface damage. As an alternative 
approach to enhance Treg populations, we also investigated the administration of microspheres 
containing one factor, which may be more translational than three different factors, and 
demonstrated the prevention of signs of DED. Taken together, all of these microsphere 
formulations aim to mimic how the body resolves inflammation and may be a potential modern 
therapeutic engineered approach for DED. 
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 xix 
ACKNOWLEDGEMENTS 
 
First and foremost, I thank my advisor, Dr. Steven R. Little, for the opportunity to pursue my 
Ph.D. and his tremendous support, patience, and guidance as a mentor. Steve has been an 
excellent mentor; providing integral direction to enhance my writing, communication, analytical, 
and problem-solving skills. My dissertation would not have been possible without his guidance.  
I also want to thank my committee members, Dr. Sanjeev Shroff,  Dr. Yadong Wang, and        
Dr. Joel Schuman for their support and instrumental mentorship throughout my Ph.D. 
dissertation.  
I would also like to acknowledge all the lab members of the Little lab for their support, 
insightful scientific comments, and assistance over the years. Thank you to the CTSI program for 
their financial and academic support, which provided me with many opportunities for 
professional growth and development. My sincere thanks to the ophthalmology core for 
providing the resources to enhance the research through the imaging, histology and flow 
cytometry facilities.  
On a personal note, I would like to thank my family and friends whom served as a 
continued motivation and support system, in particular, my growth group and bible study group. 
I would also like to especially thank my parents, Pat and Sandy, whom their patience, 
encouragement, and love has helped me throughout my graduate career. I love them so much, 
and I am incredibly thankful for their unconditional love, prayers, and providing a solid faith 
 xx 
foundation. Also, I would like to thank my sisters, Lori and Sheri, whom are my best friends that 
have provided support, encouragement and love.  I would like to thank my husband, Jeff, for his 
tremendous support, encouragement and love. There are no words to adequately covey how 
much I love you and appreciate your support. Most of all, I would like to thank God, whom is 
my Heavenly Father and the author of salvation.  
 
 
 
 1 
1.0  INTRODUCTION 
This chapter is adapted from Michelle L. Ratay, Elena Bellotti, Riccardo Gottardi, and Steven R. 
Little. (2017). Modern Therapeutic Approaches for Non-Infectious Ocular Diseases Involving 
Inflammation. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.201700733  
 
 
With the global ophthalmic drug delivery market estimated to grow at two-and-a –half times the 
overall rate of the pharmaceutical industry, many commercial opportunities exist for the 
development of new ophthalmic drugs.[1] Ideal candidates for improved drug delivery treatments 
are those ocular diseases that drastically affect patients’ quality of life including dry eye disease 
(DED), age-related macular degeneration (AMD), and uveitis.[2–4] These three common ocular 
diseases affect different regions of the eye and have immuno-mechanistic characteristics in their 
disease pathogenesis. For instance, DED affects the ocular surface and is thought to be primarily  
due to inflammation mediated by T cell infiltration.[5,6] Although, the disease pathogenesis of 
uveitis is also thought to be mediated via T cells, inflammation occurs in the uveal tract of the 
eye. On the other hand, AMD primarily afflicts the macula tissue of the eye, and is thought to be 
caused by the complement immune system (innate immunity), chronic oxidative stress, and 
neovascularization.[7,8] Though, all these diseases affect different regions of the eye and possess 
different pathology, one common underlying link associated with these ocular diseases is the 
involvement of inflammation.[7,9,10] When properly regulated, inflammation is both healthy and 
essential for the elimination of pathogens and healing. However, excessive, unregulated 
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inflammation can lead to chronic diseases where immune-mediated damage to the ocular tissues 
elicits an inflammatory response that causes further damage.[11–13] In order to either treat the 
damage caused by unregulated inflammation or halt the inflammatory cycle, current and new 
therapies have been developed.[7,14,15] Moreover, these current/new therapies (modern therapeutic 
approaches) are interdisciplinary in nature, utilizing a combination of synthetic materials, cells, 
biologics and small molecule based treatments in order to address the underlying inflammatory 
imbalance. Ultimately, these modern therapeutic approaches can even be inspired by the body’s 
own method of restoring homeostasis. Specifically, some of the methods of administration for 
these modern therapeutic approaches include: topical administration, injections, contact lenses, 
and implants.[16,17] However, there are several limitations associated with these methods of drug 
administration, such as anatomical barriers, poor bioavailability, and patient compliance issues. 
For this reason, new treatment strategies intend to address one or more of these barriers.  In this 
chapter, we will discuss the challenges of ocular drug delivery, and the currently used (and also 
new, investigative) treatments aimed at targeting the pathological factors of dry eye disease, age-
related macular degeneration, and uveitis. 
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1.1 ROUTES OF OCULAR ADMINISTRATION 
1.2 ANTERIOR SEGMENT 
1.2.1 Topical 
A key challenge of ocular drug delivery systems for the treatment of diseases affecting the 
anterior segment of the eye is to obtain therapeutic levels of drug in the ocular tissues shown in 
Figure 1, while minimizing systemic side effects.[18] Indeed, even the currently approved 
therapies for pathologies of the anterior portion of the eye (ex: DED and anterior uveitis), are 
plagued by short resident time on the ocular surface and poor bioavailability.[19]  
Currently, the standard of care for the treatment of diseases affecting the ocular surface 
and the anterior segment is the topical administration of ophthalmic medications such as eye 
drops, suspensions, gels, or ointments as shown in Figure 2.[18] Although topically administered 
drugs are generally well accepted and tolerated methods of delivering medication by patients, a 
major limitation is patient compliance, especially for individuals affected by chronic pathologies 
such as uveitis, and DED.[19,20] In fact, these pathologies require the self-administration of topical 
medication several times a day, which can severely decrease patient compliance.[21] Moreover, 
this frequent dosing may cause either systemic or local side effects due to the high amounts of 
total drug administered. Another limitation of topical formulations is their low bioavailability at 
the site of action.[22] In particular, it is reported that approximately only 5-10% of the 
administered drug reaches the target tissue, while the remaining 90-95% is eliminated.[23] This 
elimination occurs through natural, precorneal mechanisms of protection from foreign substance 
such as drainage through the nasolacrimal duct, blinking, tear film, tear turn over, and induced 
lacrimation as displayed in Figure 1.[24–26] In particular, after the administration of an ophthalmic 
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medication, the drug is first diluted in the lacrimal fluid, which reduces the effective 
concentration of the applied drug. Moreover, the precorneal tear drainage washes away topical 
medication within the first 15-30 seconds after application, reducing the amount of time the drug 
remains in contact with the ocular surface, and absorption.[27] Furthermore, another factor 
reducing the effectiveness of topical eye drops is the anatomic volume of the cul-de-sac, which is 
approximately 7-10 µL, while the dosing volume of instillation is approximately 20-50 µL.[25] 
This difference leads to either the spill of the excess volume on the cheek or to a rapid 
elimination through the nasolacrimal duct.[25] Despite these limitations, topical administration of 
ophthalmic drugs is still the most widely prescribed route of administration as it offers numerous 
advantages including noninvasiveness, ease of administration, and low absorption into systemic 
circulation.[18] Examples of topical ophthalmic drugs are those used for pathologies affecting the 
surface of the eye, such as DED, in which artificial tears and lubricants are topically 
administered to relieve symptoms.[28]  However, the development of new methods to enhance 
drug bioavailability and reduce the frequency of drug administration would greatly improve 
patient compliance and overall effectiveness of treatment. Thus, in order to improve patient 
compliance and enhance ocular drug bioavailability new alternative approaches have been 
developed, which will be discussed in following sections of this chapter. 
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Figure 1. Schematic illustration of the overall structure of the eye. 
 
 
 
 6 
1.2.2 Contact Lenses 
Therapeutic contact lenses as represented in Figure 2 have been widely studied for controlled 
and sustained drug delivery in order to overcome the limitations associated with topical eye 
drops.[29] Since contact lenses can be worn for a longer length of time, their use for the release of 
an ophthalmic medication helps to improve patient compliance by reducing the frequency of 
administration.[30] Furthermore, in comparison to eye drop formulations, contact lenses allow an 
increased residence time associated with greater than 50% more bioavailability at the site of 
action.[30] Consequently, the administered dosage to obtain therapeutic levels at the desired site 
can be reduced, limiting systemic absorption and its associated side effects.[30] Thanks to these 
advantages, drug loaded contact lenses are under investigation as a possible drug delivery system 
for pathologies affecting the surface of the eye such as DED. In particular, contact lenses for the 
release of cyclosporine have been studied in order to provide increased ocular contact time thus 
enhancing the drug bioavailability, in addition to a controlled and sustained drug release 
profile.[31] 
The simplest way to obtain drug-loaded contact lenses is by absorption of the drug 
(soaking the lens into a drug solution), which will be then released on the ocular surface.[30] The 
ability to load the drug into the contact lens strongly depends on the water content, thickness, 
concentration of drug solution, molecular weight of the drug, and soaking time.[30] Over the 
years, this technique has been used for loading contact lenses with different ophthalmic 
medications such as timolol, cyclosporine, and dexamethasone.[31–35] Despite the simplicity of 
fabricating a soaked contact lens, it can take a few hours to absorb the drug, and the amount of 
drug that can be incorporated in the lens matrix is low, especially for hydrophobic drugs.[36] 
Moreover, when the drug is incorporated into the lens matrix by soaking, it can quickly diffuse 
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out of the lens, with release times typically limited to a few hours.[36] Therefore, contact lenses 
could be a promising device to achieve sustained delivery of ophthalmic medications. However, 
their commercialization is still limited because of the need to address some issues that negatively 
impact lens properties such as transparency, ion and oxygen permeability, water content, and 
mechanical properties, each of which is coupled to the properties of the drug and the amount of 
drug that is loaded.[30] For this reason, alteration of any of these critical properties of contact 
lenses could result in affected visual ability in patients, presenting significant design challenges 
for long-term delivery with large amounts of loaded drug.  
1.2.3 Punctal Plugs 
Punctal plugs as shown in Figure 2 are a non-invasive therapeutic method and generally well 
accepted by both patients and physicians, and were originally used for treating DED by blocking 
tear drainage, thus improving tear film quantity and residual contact time.[37] Recently, punctal 
plugs have been proposed for the controlled release of topically administered medications to the 
ocular surface.[38,39] For this purpose, punctal plugs are generally coated on all sides (except the 
head portion) with a material that is impermeable to the tear fluids and the drug. Release is 
controlled through diffusion of drug following contact of the head of the plug with tear fluid. 
Common issues associated with the use of punctal plugs are eye irritation, excessive tearing, 
ocular discomfort, and spontaneous loss of the plug from the punctum.[19,40,41] However, drug 
eluting punctal plugs could offer a new approach for the treatment of chronic pathologies, thanks 
to several potential advantages over topical administration such as dose reduction, controlled 
release of drugs, reduction in the frequency of administration and potentially better patient 
compliance with the therapy.[41]  
 8 
 
 
 
 
 
 
 
 
Figure 2. Representative Image of the Anterior Segment of the eye and some examples of different 
routes of administration. 
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1.3  POSTERIOR SEGMENT 
1.3.1 Topical and Systemic Administration 
Treating the less accessible posterior segment of the eye is more challenging for topical delivery 
than addressing anterior diseases, due to the longer diffusional distance, that the drug has to 
overcome before reaching the posterior tissues, characterized by additional physical and 
diffusional barriers.[42,43] In particular, topical administration is inefficient in delivering 
medications to the posterior segment because of the rapid drainage through the nasolacrimal 
ducts, as discussed in section 1.2.1.[44] To reach the posterior segment of the eye, a topically 
administered drug must penetrate through the cornea shown in Figure 1, which represents a 
barrier from external agents that naturally serves to hinder the transport of either exogenous 
substances from the pre-corneal pockets.[45,46] The cornea allows for only the passage of small, 
moderately lipophilic molecules, while drug solutions made of macromolecules can often 
penetrate through the cornea only at very low rates, making it difficult to achieve therapeutic 
efficacy.[45] An additional challenge for topically administered drugs to reach the intraocular 
environment is represented by the blood-aqueous barrier shown in Figure 1, consisting of 
endothelial cells in the uvea and of the non-pigmented layer of the ciliary body epithelium. 
Specifically, the blood-aqueous barrier forms tight junctions that regulate the exchange of solutes 
between the anterior and posterior segments, thus impeding nonspecific drug penetration into the 
inner ocular tissues.[47,48]  
Another possible approach for locating drug molecules to the back of the eye consists in 
systemic administration (intravenous or oral), however the delivery is limited by blood dilution 
of the drug,  presence of inner and outer blood-retinal barriers shown in Figure 1, and in the case 
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of the oral route, and gastrointestinal barriers.[49] The presence of these anatomical barriers 
requires a high drug concentration circulating in the plasma to achieve therapeutic levels in the 
eye, and such high doses may result in systemic side effects.[49,50] Consequently, treating 
disorders that affect the posterior segment of the eye would greatly benefit from specific 
localized targeting that could be achieved (for instance) by the more invasive intravitreal 
injections and implants.  
1.3.2 Intravitreal Injections 
Intravitreal injection as represented in Figure 3 is a route of administration that intends to target 
the posterior segment of the eye. This approach consists in a direct delivery of the drug to the 
vitreous, thereby avoiding passage through the ocular barriers and (in turn) leading to a high 
availability of the ophthalmic medication in the posterior segment tissues.[51] Intravitreal 
injections are currently used for the administration of anti-VEGF drugs for the treatment of 
AMD and macular edema.[52,53]  
Despite the advantage of delivering medication locally, intravitreal injections are 
considered an invasive procedure with consequent potential complications, such as raised 
intraocular pressure (IOP), transient blurry vision, retinal detachment, and cataracts.[54] 
Moreover, several injections are often needed to ensure optimal therapeutic drug levels at the site 
of action due to the short half-life of most ophthalmic drugs, thus increasing the risks of side 
effects and decreasing overall patient compliance.[17,55,56] Therefore, alternative methods to 
deliver ophthalmic formulations to the posterior segment that require less frequent dosing could 
be extremely beneficial for patients, with the advantage of avoiding the aforementioned 
complications related to repeated injections, and reducing the risk of rapid clearance. 
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1.3.3 Intravitreal Implants 
Intravitreal implants can be used as controlled/sustained drug delivery systems that can 
overcome several limitations of topically, systemically, and intravitreal administered 
medications.[57] If designed appropriately, implants have the potential to promote the sustained 
delivery of relatively steady therapeutic levels of drug to the site of action over long periods of 
time with only one implantation procedure. Moreover, a significantly lower amount of drug is 
required (due to reduction in clearance and protection of the unreleased dose), thereby reducing 
the associated potential risks of systemic administration and intravitreal injections.[57] 
 Intravitreal implants are classified as either non-biodegradable or biodegradable 
polymeric devices and are each capable to release drug molecules from a few months to several 
years depending upon the design.[21] Typically, non-biodegradable implants can be utilized to 
achieve a slower rate of release over a longer period of time than biodegradable implants, 
however, they require surgical removal once the loaded drug is exhausted.[57] A non-
biodegradable implant containing fluocinolone acetonide (Retisert, Bausch & Lomb, Rochester, 
NY, United States) was the first to be approved by the FDA for the treatment of severe, non-
infectious uveitis.[58] Vitrasert® (Bausch & Lomb, Rochester, NY, United States) is another 
example of a non-biodegradable implant. Specifically, Vitrasert® is the first implantable 
ganciclovir delivery system approved for the treatment of cytomegalovirus retinitis. Clinically 
used in the United States since 1996, Vitrasert® releases the drug over a period of eight 
months.[59] Overall, non-biodegradable implants have been demonstrated to be a valid alternative 
to intravitreal injections to obtain prolonged release of the therapeutic in the posterior segment 
with only one implantation procedure.  However, despite the safety and efficacy demonstrated by 
non-biodegradable implants, surgical removal can lead to ocular complications.[57] Hence, 
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biodegradable implants that ultimately do not need to be removed (and refilled and re-implanted 
or otherwise replaced when the drug is exhausted) would be a highly desirable alternative. 
Biodegradable implants are generally composed of biocompatible polymers that either degrade 
into non-toxic byproducts, or solubilize in vivo and can be eliminated safely by the human body, 
thus avoiding permanent chronic foreign-body reaction.[60] One of the most commonly utilized 
biodegradable polymers for controlled release formulations is poly (lactic-co-glycolic) acid 
(PLGA), which is FDA approved for a number of applications.[60–62] PLGA degrades into acidic 
byproducts such as lactic acid and glycolic acid, and although adverse reactions are generally 
mild to non-detectable, the context will dictate the importance of these effects.[63,64] Notably, the 
biocompatibility of PLGA has been investigated in ocular tissues and has shown to possess 
greater tolerability than when placed in non-ocular tissues, explaining why it is still one of the 
most widely utilized biodegradable polymers for controlled release today.[60] 
One example of a biodegradable implant is represented by the bioerodible Ozurdex 
(Allergan Inc., Irvine, CA, United States), approved by the FDA for the treatment of uveitis and 
macular edema.[65] It consists in a PLGA matrix that releases dexamethasone for up to four 
months.[65] Recently, the use of Ozurdex has been investigated as additional therapy in patients 
affected by AMD and refractive to ranibizumab.[66] The results of the study suggest the 
effectiveness of the dexamethasone-based implant in stabilizing vision, thus encouraging further 
investigation of the use of Ozurdex as a possible treatment for AMD.[66] Despite the advantage of 
requiring only one procedure to be implanted, biodegradable implants (like non-degradable 
implants) can still move from the original site of injection/implantation in the intraocular 
environment. Also, if not designed properly, a sudden increase of drug release may occur.[65] 
However, recent studies have shown how these matrices degrade, which can be correlated to 
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initial conditions such as the polymer molecular weight distribution, polymer type, copolymer 
ratio, size, shape, and type of drug.[67–69] More so, these properties can be tuned to not only 
eliminate burst effect, but also to provide a customized release profile for practically any 
drug.[67–69] Overall, both non-biodegradable and biodegradable implants represent potential 
advantages and disadvantages, and represent a potential solution to the many limitations 
associated with traditional methods of administration of ophthalmic drugs.   
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Figure 3. Illustration of the Posterior Segment of the eye and a few examples of some methods of 
therapeutic administration. 
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1.4 ENGINEERED DRUG DELIVERY SYSTEMS: MICROPARTICLES AND 
NANOPARTICLES 
New biodegradable polymeric carriers with convenient size/shape, such as microparticles with 
size in the range of 1-1000 µm and nanoparticles with size of less than 1 µm, represent a 
promising tool for ocular drug delivery.[70–74] In particular, micro- and nanoparticles enable the 
achievement of sustained intraocular therapeutic drug concentrations without requiring the 
surgical implantation of a drug delivery device (as they can be injected through a needle and 
syringe), offering a release of drug that can last for weeks or even months.[57,70,75] Particulates are 
most often administered intravitreally as a less invasive procedure compared to surgical 
implantation.[57] Moreover, these particular drug delivery systems can be engineered to target 
certain cells type, reducing the risks of systemic side effects.[57] Micro- and nanoparticles can be 
classified as “micro- and nanospheres”, and “ micro- and nanocapsules”.[76]  In particular, in 
micro- and nanospheres, the drug and polymer are typically combined, and the drug is dispersed 
throughout the polymeric matrix.[76] In such a matrix system, the release of the active molecules 
is controlled by diffusion through the polymer matrix with simultaneous polymer degradation, 
which will non-linearly increase the diffusivity over time.[77] On the other hand, in micro-and 
nanocapsules, the drug particles or droplets are entrapped in a polymeric membrane.[76] Active 
molecules can be encapsulated in micro and nanocapsules via an emulsion-diffusion procedure 
(for example) while solvent evaporation techniques are used to fabricate drug-loaded micro and 
nanospheres (for example).[78,79] 
Micro and nanoparticles can be formulated from a variety of polymeric materials. 
However, the most commonly used synthetic polymers consist in aliphatic polyesters such as 
polycaprolactone (PCL) polylactic acid (PLA), polyglycolic acid (PGA), and PLGA, due to the 
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advantages that characterized such polymers, as stated in the previous section.[80–82] As discussed 
in the prior section, the desired drug release profile can be engineered through varying the 
molecular weight of the polymer and copolymer formulation (as well as other formulation 
variables), allowing the tuning of the duration of release that can range from weeks to months.[83] 
One example of PLGA microspheres that are capable of providing one-month of release of an 
ophthalmic medication following subconjunctival injection has been recently developed.[84] 
Specifically, an in vitro study suggests that sustained release of the drug can be achieved with an 
amount of medication that is well above the lower limit of absorption for the entire period of the 
study.[84] Moreover, microspheres that were subconjunctivally injected in New Zealand white 
rabbits led to no observable foreign body response or infection over the course of one month.[84] 
Additionally, PLGA-based release systems have been studied as a promising candidate for the 
treatment of DED and uveitis, and they have been demonstrated a valid candidate for sustained 
release of therapeutics after a single administration through injection into ocular tissues.[85,86] In 
addition, a unique gelling, eye drop-like formulation has been recently reported that is able to 
comfortably retain the therapeutic drug in the lower fornix (topically) for a period of one month, 
while simultaneously releasing glaucoma medication over the period of time (without any 
injection into the ocular tissues).[87] Although micro- and nanoparticles seem to possess 
significant potential as ocular drug delivery systems, limitations include encapsulation efficiency 
of drug (especially in smaller, nanoparticle formulations with high surface area), stability of the 
molecules during particle fabrication, control of particle size and drug release rate, and large-
scale manufacturing of sterile preparations.[83]  
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1.5 AGE-RELATED MACULAR DEGENERATION 
1.5.1  Background on the Pathology of AMD 
Age-Related Macular Degeneration (AMD) is the leading cause of blindness in the elderly 
population with an average estimated Medicare cost of 724 million dollars in the United States 
alone.[88,89] The disease affects the central areas of the macula region of the retina, composed of 
light sensing cells that enable central vision.[90] When the central area of the macula is impacted, 
retinal pigment cells begin to slowly degenerate leading to blurry central vision and 
metamorphopsia (a type central visual distortion).[90] Although, most vision loss occurs in the 
advanced stages of the disease, the early onset can be characterized by the presence of drusens 
(hard/soft yellow deposits formed from acellular debris under the retina) and/or retinal 
pigmentary abnormalities as shown in Figure 4.[8,91] As the disease progresses this can lead to a 
chronic inflammatory response, resulting in the formation of retinal atrophy (also known as 
“geographic atrophy”), and/or the secretion of angiogenic cytokines (ex: vascular endothelial 
growth factor-VEGF). Ultimately, these pathological features have been classified into two 
distinct, advanced clinical classification stages.[91]  
The two advanced stages of the disease are characterized as either dry/non-neovascular 
AMD or wet/neovascular AMD seen below in Figure 4.[91] Dry/non-neovascular AMD causes 
slow degradation of vision due to the loss of photoreceptors and development of geographic 
atrophy.[91] On the other hand, wet/neovascular AMD is characterized by choroidal 
neovascularization, leading to sub retinal fluid, retinal pigment epithelium detachment, and 
formation of fibrotic scars  as shown in Figure 4.[8,89] Typically, these clinical signs can be 
diagnosed during examination using fluorescent angiography (fluorescein highlights leaky 
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vessels), which is a useful diagnostic tool to identify choroidal neovascularization, and optical 
coherence tomography (OCT) to detect thinning of the macula tissue.[91]  Upon diagnosis, 
preventative therapies such as PreserVision (a vitamin and mineral supplement), may be 
prescribed to abate the risk of advanced stage AMD and the associated vision loss. [92]However, 
this therapy may not be useful for all patients. For instance, the use of supplements such as beta-
carotene can increase the risk of lung cancer in smokers.[91] In addition, high doses of vitamin E 
can increase the risk of heart failure in patients with diabetes and heart disease.[91]  
Due to the potential side effects, studies have examined the pathogenesis of the disease in 
order to develop new effective therapies.[93–95] New studies of AMD progression suggest that 
disease is associated with higher levels of biomarkers that are indicative of inflammation.[7] It is 
currently thought that the activation of the innate immune system, upregulation of complement 
factors, and the secretion of chemokines and cytokines lead to ocular tissue damage in AMD.[7,11]  
Although the full pathogenesis has not been elucidated, current (and experimental) treatments 
have attempted to address the local inflammation in order to decrease the progression of vision 
loss displayed in Table 1.[11,90,96]  
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Table 1. Summary of AMD Treatments. 
 
Treatment Type of Study Results Ref. 
Rapamycin Preclinical- Rat The oral administration of rapamycin was able to lessen 
abnormalities of the retinal tissue observed in ocular 
histological sections. 
[97] 
Doxycycline Murine Lower expression levels of M-2 type macrophages markers 
such as Arg1 and reduced neovascularization were detected 
with the administration of doxycycline. 
[98] 
HIF-Antagonist Murine The hypoxia-inducible factor (HIF-1) antagonist has shown to 
reduce levels of pro-angiogenic factors in choroidal 
neovascularization and may serve as a treatment for wet AMD. 
[99] 
Anti-VEGF Clinical Ranibizumab (Lucentis) and Bevacizumab (Avastin) are both 
VEGF-A monoclonal antibodies, which have demonstrated 
clinical efficacy as a therapy for wet AMD. Although, this 
treatment may lead to hemorrhage and cataract formation.  
[52,100] 
 
 
 
Gene Therapy Murine  Preclinical and phase I human trails demonstrated that an 
adenoviral vector expressing pigment epithelium-derived factor 
(PEDF) lessened choroidal neovascularization.  
[101] 
Complement Inhibition   In Phase II clinical trials, Lampalizumab                
 (a humanized monoclonal antibody fragment) has shown to 
inhibit a component of the complement immune system thereby 
reducing geographic atrophy observed in AMD. 
 
[93,102] 
IL-18 Murine/Primate Administration of IL-18 reduced choroidal neovascularization 
in non-human primates.  
 
[103] 
Human Embryonic  
Stem Cells (hESCs) 
Rodent/Clinical Transplanted hESCs in the subretinal space of rodents was able 
to maintain visual function. In addition, to assess safety of 
transplanted hESC-derived RPE in humans, a  clinical trial was 
performed. The subjects did not have any adverse effects from 
the stem cells. 
 
[104,105] 
Induced Pluripotent Stem 
Cells (iPSCs) 
Human An iPSC trial completed in Japan demonstrated that the stem-
cells were able to prevent the loss of vision in a woman with 
AMD. Although, the genetic mutations were observed in the 
cells of the other trial subject and thus the trial was halted.  
[106,107] 
Retinal Progenitor Cells 
(RPCs) 
Murine A scaffold composed of poly (lactic) acid and poly (lactic-co-
glycolic) acid seeded with RPCs was able to enhance survival 
of RPCs. Additionally, a polycaprolactone scaffold was utilized 
to seed  
stem cells.     
[108–
110] 
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Figure 4. Characteristic features associated with the pathology of Age-Related Macular 
Degeneration. (A) Intermediate state of AMD with drusen (B) Loss of retinal pigment epithelial cells and 
choroidal vessels. (C) Neovascular AMD with retinal hemorrhage. Reproduced with permission. [160] 
Copyright 2009, Elsevier, The Lancet  
 
 
 
1.5.2 Anti-Inflammatory Therapy Based Treatments for Age-Related Macular 
Degeneration 
1.5.2.1 Immunosuppressive Agent: Rapamycin 
Rapamycin (Sirolimus) is an immunosuppressive treatment utilized for a several conditions, such 
as organ transplantation and ocular inflammatory diseases.[11,111,112] Rapamycin inhibits a 
downstream target known as mTOR (mammalian target of rapamycin) that is needed for 
upregulation of IL-2 production, which sustains T cell activation and proliferation.[111] The 
mTOR pathway has also been linked to effects on cellular aging; therefore, mTOR inhibitors, 
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such as rapamycin, prevent the conversion of quiescence to senescence, which has revealed to 
slow down aging in mice.[97] Slowing down the aging process with rapamycin may also be 
relevant to the progression of age-related diseases such as AMD.[97] Kolosova et al. demonstrated 
rapamycin could affect retinopathy in senescence-accelerated AMD rat model by reducing 
histological abnormalities of the ocular retinal tissue.[97] Overall, pre-clinical evidence suggest 
rapamycin did not cause any adverse side-effects when administered orally and may have a 
potential advantage due to its low renal toxicity.[111]  
1.5.2.2 Doxycycline  
Doxycycline (as described in section 1.7.2.3) has also exhibited anti-inflammatory and anti-
angiogenic properties, making it a potential candidate for the treatment of AMD.[113] He et al. 
hypothesized that inhibiting the polarization of a subset of pro-angiogenic immune cells, M2 
type macrophages, with doxycycline could lead to lower expression levels of pro-angiogenic 
cytokines and thereby diminish neovascularization.[114] To test this hypothesis, mice were 
injected intraperitoneally with doxycycline one day prior to exposing them to laser 
photocoagulation (to cause choroidal neovascularization injury) and, thereafter, doxycycline was 
injected daily until the conclusion of the study.[114]  With the administration of doxycycline, there 
was a significant reduction in the expression of the M2-type macrophage markers such as Arg1 
and subsequent neovascularization.[114] Furthermore, doxycycline can inhibit choroidal 
neovascularization in other experimental pre-clinical models.[113] Even though, pre-clinical 
studies demonstrate doxycycline had a significant effect on neovascularization, there are other 
types of anti-angiogenic treatments that do not require daily systemic administration.[52,115]   
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1.5.3 Anti-Angiogenic Treatments for AMD  
1.5.3.1 Sustained Delivery of a HIF-Antagonist 
Pro-angiogenic factors can cause disease progression of AMD, and specific promoters for genes 
encoding these pro-angiogenic factors have been identified.[99] These promoters possess a 
hypoxia response element, and they are activated by the hypoxia-inducible factor-1 (HIF-1).[116] 
Consequently, a possible strategy to block pro-angiogenic factors is to develop inhibitors of HIF-
1, since it is involved in the upregulation of many pro-angiogenic factors.[99] In particular, 
doxorubicin (DXR) has been demonstrated to be a potent inhibitors of HIF-1-mediated gene 
transcription by blocking the binding of HIF-1 on DNA.[99] For instance, it has been 
demonstrated that DXR released from polymeric particles was able to significantly reduce the 
levels of different pro-angiogenic factors (VEGF-A, PDGF-BB, and SDF-1) in an established 
pre-clinical model of choroidal neovascularization.[99] Accordingly, these results demonstrate the 
ability of DXR to suppress HIF-1, representing a promising approach that may be effectively 
applied as a treatment for AMD. 
1.5.3.2  Anti-VEGF Therapy 
The pro-angiogenic vascular endothelial growth factor A (VEGF-A) plays a role in disease 
propagation.[52] To directly hinder the effects of VEGF-A, new anti-VEGF treatments have been 
developed, such as Ranibizumab (Lucentis) (a recombinant monoclonal antibody), which 
promises significant improvement in visual acuity and reduced angiographic lesions after a two-
year clinical follow-up of a multicenter clinical trial.[52,117] Ophthalmologists originally began 
treating neovascular AMD off-label with bevacizumab (Avastin), another VEGF-A monoclonal 
antibody originally developed as a treatment for advanced colon or rectal cancer, and costs less 
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than Ranibizumab.[100] Although bevacizumab was being used off-label, there was an absence of 
clinical-trial data supporting its use for AMD. Therefore, the Comparison of Age-Related 
Macular Degeneration Treatments Trials (CATT) compared the efficacy and safety of 
bevacizumab to ranibizumab. The results indicated both drugs possessed similar efficacy 
concerning visual acuity.[100] Despite the clinical efficacy of anti-VEGF therapies for AMD, 
these medications can increase the risk of thromboembolic events, and intravitreal injections 
have been associated with several risks including cataract formation, bacterial endophthalmitis, 
hemorrhage, and retinal detachment.[90] In order to avoid these side effects, gene therapies for 
AMD have been explored as ways to enable effective suppression of the VEGF pathway.[96,107]  
1.5.4 Gene Therapy for AMD 
A different therapeutic strategy that could resolve the issue of the short half-life of protein-based 
treatments may be the use of viral vectors to deliver sustained transgene expression of anti-
angiogenic factors.[118,119] Specifically, approaches using an adenoviral vector expressing 
pigment epithelium-derived factor (PEDF) to counteract the effects of VEGF have been 
evaluated in pre-clinical (ex: primate) and phase I human trials.[101,118] Evidence from these 
investigations reported lessened choroidal neovascularization and no significant adverse events 
or dose-limiting toxicities were observed.[119]  In spite of this evidence, there are still concerns 
surrounding the possible side effects of gene therapy. In particular, viral vectors can induce T-
cell responses against the expressed transgene products, and recent evidence has also 
demonstrated that the usage of viral vectors can result in mutagenesis, ultimately leading to 
cancer.[107]  Overall, more investigation is warranted for gene- based therapies.   
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1.5.5 Complement Inhibition 
An underlying factor that is linked to the development of AMD is activation (or deregulation) of 
the complement system.[7,102] Activation of complement pathways leads to a membrane attack 
complex (MAC), which can result in cell lysis, the release of chemokines and increase of 
capillary permeability.[102]  A member of the chymotrypsin family of serine proteases known as 
complement factor D (CFD) is an enzyme involved in regulating the alternative complement 
pathway.[93] Moreover, some of the factors that influence the alternative complement pathway 
include genetic variations associated with CFD gene single nucleotide polymorphisms (SNP) and 
AMD.[93]  Due to the association between AMD and genes encoding aspects of the complement 
system, new AMD therapies have been investigated to block components of the complement 
system. Specifically, Lampalizumab (Anti-Factor D), a humanized monoclonal antibody 
fragment administered intravitreously acts to inhibit CFD involved in the amplification of the 
alternative pathway.[93] In a Phase II study, there was a reduction of  disease progression in 
patients treated with anti-factor D.[120] As Phase III clinical trials have begun, evaluations will be 
required to determine whether the immunogenicity of these types of antibody-based therapeutics 
can cause any undesirable immunological responses potentially impacting drug efficacy.  
1.5.6 IL-18 Therapy 
Drusens contribute to the activation of an inflammatory response through NLRP3 
inflammasomes.[95] When stimulated by a damage signal, NLRP3 forms an inflammasome, 
which leads to the activation and secretion of IL-1β and IL-18.[95] Interestingly, studies on IL-1 
receptor knockout mice demonstrated that IL-1 did not have a significant effect on the 
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progression of AMD (choroidal neovascularization). While on the other hand, injecting IL-18–
neutralizing antibodies resulted in a significant increase of choroidal neovascularization 
development. This suggests that IL-18 might prevent the formation of vascularization.[95] 
Building upon this evidence, tolerability and efficacy of IL-18 was explored in a mouse and non-
human primate model of AMD.[103] Notably, the images seen below in Figure 5, suggest  that 
IL-18 could prevent the choroidal neovascularization in AMD.[103] Ultimately, the administration 
of IL-18 reduced the pathology associated with AMD in both murine and non-human primate 
models, suggesting that this new type of immune-therapy may be able to prevent AMD 
progression.[103]  
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Figure 5. (A) Representative images of fundus fluorescein angiography show a reduction of 
fluorescein stained lesions in the treatment (IL-18) group (B) The amount of fluorescein lesions were 
significantly decreased in the IL-18 group suggesting that the immunotherapy, IL-18, can prevent choroidal 
neovascularization. Modifications/Reproduced with permission.[180] Copyright 2015, Investigative 
Ophthalmology and Visual Science. 
 
 
1.5.7 Cellular-Based Therapies 
1.5.7.1  Human Embryonic Stem Cells (hESCs)  
New stem cell-based treatments are being investigated to regenerate the retinal pigment epithelial 
cells that are destroyed in AMD.[121] For example, the use of human embryonic stem cell-derived 
retinal pigment epithelial cells (hESC-derived RPE) preserved visual function and ensured the 
health of the photoreceptors in a rodent model.[121]  Moreover, the administration of hESCs did 
not result in the formation of a teratoma (tumor) in the sub-retinal area of transplantation, and 
ultimately, the long-term data suggested that hESCs did not result in adverse pathological 
reactions. [121] 
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In addition to a long-term pre-clinical rodent test, two prospective phase I/II clinical 
studies were designed to examine the medium- and long-term safety of human embryonic stem 
cells (hESCs) transplanted into patients.[104] Primary endpoints of safety were assessed 
concerning the sub-retinal transplantation of hESC-derived RPE in AMD subjects that received 
three different cell doses and were followed for 22 months.[104] The evidence collected in this 
trial indicated that patients did not suffer from any adverse rejection, nor from any systemic 
effect from the transplanted cells.[104] However, even though no serious adverse effects were 
observed, there are still concerns associated with the use of embryonic stem cells, because they 
have been known to form teratomas in some pre-clinical models.[105] Furthermore, use of hESC-
derived RPE cells is ethically and politically controversial since the stem cells originate from 
human embryos.[105]  
1.5.7.2  Induced Pluripotent Stem Cells (iPSCs) 
Induced pluripotent stem cells (iPSCs) derived from retinal pigment epithelia cells were 
proposed as an alternative to hESCs as they bypass some of the associated ethical concerns. 
Although iPSCs have progressed from pre-clinical to clinical trials,[106,122] there are still concerns 
about their potential immune rejection.[122] The promise of iPSC therapy and potential concerns 
were both highlighted by a recent clinical study carried out in Japan.[122] In this trial, iPSCs were 
transplanted into a woman with AMD, and resulted in improved prevention of vision loss.[122] 
However, the stem-cell trial was halted after genetic mutations that can potentially carry the risk 
of cancer, were discovered in the cells of the second trial participant.[122] Overall, this clinical 
trial demonstrated that additional investigation is required to examine the potential 
immunogenicity, possibility of genetic mutations leading to cancer, and likely requirement of 
immunosuppressive drugs before iPSCs therapy is implemented as a safe clinical treatment. 
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1.5.7.3  Retinal Progenitor Cells (RPCs) 
Retinal progenitor cells possess the ability to differentiate into unique types of retinal cells such 
as photoreceptors, and may be utilized as a cellular-based therapy for the treatment of AMD.[109] 
However, delivering living cells into an unorganized and inflamed ocular microenvironment 
could affect cell survival.  For this reason, new tissue-engineering approaches (such as scaffolds) 
can potentially provide a unique micro-environmental to enable cells to differentiate and 
organize into functional layers to repair damaged tissue.[110] For instance, porous, biodegradable 
scaffolds composed of a combination of poly (L-lactic acid) and PLGA were fabricated, and 
subsequently RPCs were seeded on the scaffold and cultured shown in Figure 6.[109] An in vivo 
study was performed on rats using the polymer scaffolds seeded with RPCs, which demonstrated 
that the implantation of the seeded scaffold enabled enhanced survival of the RPCs.[109] In 
addition, another study explored a 3-D thin-film, polycaprolactone-based scaffold seeded with 
retinal progenitor cells to treat AMD.[108] The cells were able to stay in close contact with one 
another, the porosity allowed for diffusion of nutrients, and provided an environment for the cells 
to adhere.[108] Overall, three-dimensional polymer-based scaffolds are a new, promising approach 
to provide an environment that enhances therapeutic cell survival, proliferation, and 
differentiation. 
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Figure 6. SEM micrographs of PLGA-based scaffolds fabricated using a phase-inversion technique. 
(A) Representative image of the water-exposed side. (B) Representative image of the glass side.                      
(C) Representative image of the cross section. Reproduced with permission, can prevent choroidal 
neovascularization. Modifications/Reproduced with permission.[180] Copyright 2015, Investigative 
Ophthalmology and Visual Science. 
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1.6 UVEITIS 
1.6.1 Background on the Pathology 
Uveitis is a term used to refer to various inflammatory conditions of the eye, and is often 
associated with irreversible ocular damage, visual impairment or blindness, and with consequent 
reduction in the quality of life.[123] Uveitis is estimate to causes 10% of visual loss in the United 
States each year, and up to 25% of cases in the developing countries.[124,125] Approximately 70-
90% of patients aged between 20-60 years, which represents the age range where individuals are 
most productive from an economical point of view, are most affected by uveitis. In particular, 
when vision is lower than 20/40, the ability of a person to accomplish tasks in her/his productive 
years is impaired.[126] This leads to a significant encumbrance to the US economy, with cost 
estimated to be around 242.6 million dollars each year.[15]  
Uveitis typically starts in the uveal tract (ciliary body, iris and choroids), but it can also 
affect other  structures including vitreous humor, retina, vessels and optic nerve.[127] The disease 
can be of either infectious or non-infectious nature.[128] Specifically, infectious uveitis is the most 
common form, representing approximately 15-20% of all cases in the United States.[129] It is 
initiated through an immune response directed against exogenous pathogens such as viruses, 
fungi, parasites, and bacteria.[130] Infectious uveitis can affect different parts of the eye, leading 
to either anterior or posterior uveitis.[129] However the most devastating cases are those causing 
posterior involvement such as acute retinal necrosis due to herpes viruses or toxoplasmosis 
retinochoroiditis.[129]   
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Conversely, non-infectious uveitis is often autoimmune-oriented, and is associated with 
systemic pathologies (for example sarcoidosis, Vogt-Koyanagi-Harada syndrome, Behçet’s 
disease), or local conditions such as punctate inner chorioretinopathy, birdshot 
chorioretinopathy, multifocal choroiditis, and serpiginous chorioretinopathy.[131] Non-infectious 
uveitis is the result of an abnormal response of the immune system to retinal soluble antigens (S-
Ag) or interphotoreceptor retinoid-binding protein (IRBP). Such response leads to a non-
infectious inflammation of the eye, which is mediated by T-cells and propagated by pro-
inflammatory cytokines.[13,132,133] In particular, during natural development, T-cells migrate from 
the bone marrow to the thymus, where they differentiate and “learn” how to recognize self-
antigens that make up our own tissues. However, thymic education is not always effective, and 
inadequate elimination from the thymus of effector T-cell precursors that are able to recognize 
antigens may lead to circulating, non-tolerized T-cells in healthy individuals.[134] Moreover, 
when non-tolerized T-cells become activated when exposed to retinal or cross-reactive antigens 
these cells can differentiate into pathogenic effector T-cells, which can ultimately migrate to the 
eye. Consequently, this can result in a cascade of inflammatory events initiated by the 
recognition of ocular antigen by these T-cells, ultimately resulting in the breakdown of the 
blood-retinal barrier and the recruitment of leukocytes from circulation, which leads to the ocular 
inflammation observed in uveitis.[131,134,135] In order to better elucidate the pathophysiology of 
non-infectious uveitis and develop new therapies, preclinical models of experimental 
autoimmune uveitis (EAU) have been investigated.[4,136,137] The most common EAU models 
utilize mice and rats by actively immunizing them with retinal antigens (S-Ag or IRBP), which 
are recognized by lymphocytes of uveitis patients.[138] Some of the characteristics of EAU in 
animals are retinal vasculitis, photoreceptor damage, retinal and/or choroidal inflammation, and 
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loss of vision function, thus reproducing the main clinical-pathological features of human 
uveitis.[138] Different stages of the EAU model are shown in Figure 7. In particular, mice 
immunized using IRPB are characterized by a decrease in retinal inflammation severity over 
time, while chronic inflammation persists for more than 120 days post immunization as seen in 
Figure 7.[139] Moreover, optic disk images have confirmed inflammation characterized by retinal 
edema and vasculitis  in Figure 7B with presence of active and old lesions in the chronic stage of 
EAU observed in Figure 7E and 7G.[139] Overall, EAU models have been revealed as a valid 
tool toward a better understanding of uveitis, thus helping the development of current and new 
therapeutic strategies for managing the associated inflammation described in Table 2. 
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Figure 7.  Images showing retinal inflammation characterizing EAU in mice at different time periods 
after immunization using IRPB. (A) Non-immunized mouse retina. (B) Mouse fundus (25 days post 
immunization) characterized by severe optic disk inflammation and vasculitis (white arrows). (C) Mouse 
fundus (60 days post immunization) characterized by retinal atrophy, vascular sheathing (white arrows), and 
small retinal infiltrates. (D) Mouse fundus (80 days post immunization) characterized by inferior vitreous 
infiltrates (asterisks) and vascular sheathing. (E) Mouse fundus (80 post immunization) characterized by 
multiple infiltrates. The blue arrow indicates an area of gliosis or scar. (F) Mouse fundus (90 days post 
immunization) characterized by vascular sheathing (white arrow) and multiple retinal infiltrates (white 
arrowheads). (G) Mouse fundus (120 days post immunization) characterized by large scars. (H) Mouse 
fundus (120 days post immunization) characterized by pigment deposition. (I) The retinal inflammation in 
the images was quantified with a clinical score and grouped according to the time period after immunization. 
Reproduced with permission.[207] Copyright 2012, American Society for Investigative Pathology. 
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Table 2. Summary of Uveitis Treatments. 
 
Treatment Type of study Results Ref. 
Corticosteroids Human Topical corticosteroids are effective in controlling inflammation in 
anterior uveitis. Periocular or intraocular injections or oral 
administration are required for treating posterior uveitis. 
 
[123,127] 
 
Methotrexate Human This folic acid analog has demonstrated to be effective in controlling 
inflammation. 
[140] 
Mycophenolate 
mofetil 
Human This prodrug of mycophenolic acid has shown to control intraocular 
inflammation, and improve or stabilize visual acuity. Mycophenolate 
mofetil is well tolerated by patients with low recurrence of uveitis. 
 
[141,142] 
 
 
Cyclosporine Human Cyclosporine is effective in controlling inflammation with sustained 
effects even after the reduction of corticosteroids. In a retrospective 
cohort study, cyclosporine has been demonstrated  to control 
inflammation at six months and one year. 
 
[143–
145] 
 
 
Tacrolimus Human Tacrolimus is an antibiotic impairing T-cell activity and cytokine 
production. The drug has demonstrated to possess a more favorable 
safety profile than cyclosporine. 
[146–
148] 
Anti-TNF-α Human Infliximab (Remicade, Janssen biotech Inc., Titusville, NJ) is a 
monoclonal antibody antagonist of TNF-α. It has been shown to 
effectively suppress occurrence of uveitis attacks. 
[149,150] 
Anti-IL-2 - 
Daclizumab 
Human A phase I/II single armed interventional study has provided preliminary 
evidence that regular infusions of daclizumab can be administered for 
years as an alternative to standard immunosuppressive drugs.  
[151] 
Anti-IL-17A Human Secukinumab (Novartis Pharma AG, Basel, Switzerland) is a 
monoclonal antibody antagonist of IL-17A. Phase III studies have 
shown secukinumab has beneficial effects for patients with non-
infectious uveitis.  
[152] 
Anti-CD28 - 
Abatacept 
Human Abatacept (Bristol-Myers Squibb, New York, NY, United States) is a 
treatment for JIA-related uveitis. Several studies have supported its 
efficacy in controlling JIA-uveitis in children and young adults.  
[153–
155] 
Retisert Human Retisert (Bausch and Lomb, Rochester, NY, United States) is an FDA 
approved non-biodegradable implant containing fluocinolone acetonide. 
A double blind, prospective case series has demonstrated an 
improvement or stabilization of visual acuity, with no recurrence of 
ocular inflammation. 
 
[156,157] 
Cyclosporine-
releasing 
microparticles 
Animal model - 
Rabbits 
Cyclosporine-loaded microparticles have shown sustained concentration 
of cyclosporine in choroid-retina and iris-ciliary body for at least 65 
days after intravitreous injection in a rabbit model. 
[87] 
Gene therapy  
 Ad-IL-10 
Animal model - 
Rats 
Systemic administration of Ad-IL-10 in rats has shown to reduce 
leukocyte infiltration and subsequently decrease inflammation in the 
anterior chamber. 
[158] 
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1.6.2 Anti-Inflammatory Based Treatments for Uveitis 
1.6.2.1  Corticosteroids 
Corticosteroids are the primary anti-inflammatory therapy utilized for the treatment of non-
infectious uveitis.[15,159] Corticosteroids have different methods of action to manage the 
inflammation, as discussed in section 1.7.2.2.[160] As therapeutic strategy for uveitis, 
corticosteroids can be administered systemically, such as oral prednisone or intravenous 
methylprednisolone sodium succinate, or topically in the form of injections.[15] The choice of the 
most appropriate route of administration of corticosteroid strongly depends on the site and 
activity of uveitis. In particular,  topical administration of corticosteroids is effective in treating 
anterior uveitis, but the drug does not typically penetrate adequately to the posterior segment.[123] 
For this reason, topical corticosteroids may not be an ideal effective treatment for posterior 
uveitis, which often requires periocular or intraocular procedures or oral administration of 
corticosteroids.[123,127] Accordingly, long-term administration can lead to many side effects 
including hypertension, diabetes, cataract, and glaucoma.[161] To reduce corticosteroid dose and 
associated side effects, immunosuppressive agents such as methotrexate, mycophenolate mofetil, 
cyclosporine, or tacrolimus are administered as steroid-sparing agents.[161] 
1.6.2.2  Methotrexate 
Methotrexate is an analog of folic acid that irreversibly binds and inactivates dihydrofolate 
reductase, resulting in the inhibition of rapidly dividing cells such as lymphocytes.[15,161] 
Methotrexate was first introduced in 1948 as an antineoplastic agent, and subsequently found to 
have anti-inflammatory effects.[140]  The FDA approved the use of methotrexate as a treatment of 
rheumatoid arthritis in 1988, becoming the standard antirheumatic drug.[140,162] Moreover, 
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methotrexate is a commonly used immunosuppressive agent for the treatment of ocular 
inflammation, and it can be administered orally, parenterally, or by intraocular injection.[15,162] In 
particular, in uveitis patients methotrexate has demonstrated to be effective for controlling 
inflammation and for achieving corticosteroid-sparing.[140] Even if several months may be 
required for therapeutic success, methotrexate is generally well tolerated by most patients, and it 
seems to have little risks of serious side effects.[162] 
1.6.2.3  Mycophenolate mofetil 
Mycophenolate mofetil (MMF) is a pharmacologically inactive drug (prodrug) that, after 
administration, is metabolized to its active form, the mycophenolic acid.[163] MMF suppresses the 
immune system by inhibiting inosine-5-monophosphate dehydrogenase, thus selectively halting 
T and B lymphocyte replication.[164] It is currently used as a treatment for organ transplant 
rejection and for several autoimmune diseases.[15] The efficacy of MMF therapy has been 
demonstrated in the treatment of posterior segment intraocular inflammation even when 
cyclosporine and tacrolimus were not effective. Moreover, MMF inhibits the development of 
EAU,[165] and its use in the treatment of uveitis is well documented.[141,166,167]  In particular, 
MMF is effective both in combination with steroids or another immunomodulatory treatments, 
and also as monotherapy.[15] MMF is generally well tolerated by patients, with a low recurrence 
of the pathology after discontinuation of the therapy, as demonstrated in a retrospective study of 
60 uveitis patients.[141] In addition, MMF can be used as a safe and well tolerated 
immunosuppressant for the treatment of uveitis in children, with the possibility to decrease the 
dose of systemic steroids required to control inflammation.[142]  
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1.6.2.4  Cyclosporine 
Cyclosporine is often topically used for the treatment of immune-mediated ocular pathologies 
involving activation of T-cells, as mentioned in section 1.7.2.4.[168] As a treatment for patients 
with uveitis, cyclosporine is effective in controlling inflammation, and its effects are sustained 
even after the reduction of corticosteroid dosage.[144,169] For example, a retrospective cohort 
study on 373 patients demonstrated clinically acceptable control over inflammation at 6 months 
and 1 year for 33.4% and 51.9% of patients, respectively.[145] Despite the efficacy in managing 
the inflammation, cyclosporine can lead to severe nephrotoxicity,[170,171] and in addition, some 
patients can be refractory to treatment.[172] 
1.6.2.5  Tacrolimus 
Tacrolimus is an antibiotic that also impairs T-cell activity and cytokine production via 
inhibition of the calcineurin enzyme.[146] Tacrolimus was initially approved as a systemic 
immunosuppressant for liver transplantation, and currently has a broad range of usage.[146] For 
instance, tacrolimus is a treatment of choice in uveitis patients refractory to cyclosporine either 
because of lack of therapeutic effect or undesirable side effects.[173] Additionally, even though 
tacrolimus and cyclosporine can have similar efficacy for posterior and intermediate uveitis, 
tacrolimus therapy has exhibited a more favorable safety profile.[147] In the treatment of uveitis, 
tacrolimus has been demonstrated to be effective over time.[148] Studies have also shown that 
corticosteroids can be withdrawn in patients treated with tacrolimus.[174] 
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1.6.3 Biological Therapeutic Approaches 
1.6.3.1  Anti-TNF-α  
Anti-TNF-α was identified as a potential candidate for the treatment of  patients affected by 
uveitis, who either did not show an improvement in disease symptoms or did not tolerate 
traditional immunomodulatory therapies.[160,175] TNF-α is a pro-inflammatory cytokine, which 
has been implicated in a number of immune-mediated pathologies, including intraocular tissue 
damage associated with uveitis.[176] Specifically, TNF-α recruits leukocyte to the eye in the 
initial phase of uveitis and favors the adhesion of leukocytes to the vascular endothelium. TNF-α  
is also a crucial factor in the dendritic cell maturation, macrophages activation, activation of 
effector function of infiltrating T cells, as well as in the apoptosis of resident ocular cells.[176] 
Moreover, it has been indicated that intraocular levels and expression of TNF-α are high during 
the course of EAU, and systemic neutralization of TNF-α has a suppressive effect on the severity 
and incidence of EAU.[176,177] Since TNF-α plays an integral role in the propagation of EAU, the 
use of biological therapies to block the action of TNF-α has been investigated. One example of 
such is Infliximab (Remicade, Janssen Biotech Inc., Titusville, NJ), a monoclonal antibody 
acting against TNF-α.[149] Its efficacy has been extensively studied as a treatment for many 
different diseases, including spondiloarthritis, ulcerative colitis, and sarcoidosis, and its use has 
been also explored for the treatment of uveitis.[178–180] Intravenous administration of Infliximab 
results in a half-life of 9.5 days, however the drug is usually given every 4-8 weeks in the 
maintenance phase of treatment, since the biological effects extend beyond its serum half-
life.[176]  
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Several studies have reported the efficacy of Infliximab for the treatment of non-
infectious uveitis. For example, the effects of infliximab on the occurrence of uveitis attacks and 
on visual prognosis were investigated in patients affected by uveitis resulting from Behçet’s 
disease. Moreover, patients involved in the trial did not have any therapeutic effect with the 
combination therapies of  azathioprine, corticosteroids, and cyclosporine.[150] The results from 
this trial suggest that Infliximab can effectively suppress the occurrence of uveitis attacks. 
Moreover, Infliximab has a corticosteroid-sparing effect, and positive consequences for the 
visual prognosis were observed.[150] However, the beneficial effects of visual acuity are not 
necessarily preserved over time.[150] Moreover, in another study, the efficacy of low-dose (<10 
mg/kg), moderate-dose (≥10-15 mg/kg), and high-dose (≥15-20 mg/kg) of Infliximab for the 
treatment of uveitis was compared.[181] Although the administration of infliximab had beneficial 
effects in treating uveitis, an increase in dose up to four times above the approved dosage was 
often necessary to control the disease. In addition, the study highlighted that doses <10 mg/kg 
administered every four weeks may not be sufficient.[181] Overall, the high dose administration of 
Infliximab has not caused concern of serious side effects, suggesting it is a relatively safe 
treatment approach for uveitis. 
1.6.3.2  Anti-IL-2  
IL-2 is a cytokine regulating lymphocyte homeostasis and function. Studies in EAU models 
suggest that IL-2 is one of the predominant cytokines produced in the early phases of the 
disease.[182] One example of anti-IL-2 therapy is represented by daclizumab, a humanized 
blocking monoclonal antibody acting against an epitope of the alpha subunit of the IL-2 receptor 
(CD25), which is located on activated T-cells and other immune cells.[183] Daclizumab has been 
used in patients experiencing acute reaction episodes following organ transplantation, including 
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heart,  pancreas, liver, and lung. The use of daclizumab for the treatment of intraocular 
inflammation, including uveitis, has been investigated in a multicenter, non-comparative, 
interventional case series.[184–189]   In this study, daclizumab was subcutaneously administered to 
investigate the possibility of whether the drug could safely reduce the need of standard systemic 
corticosteroids or other immunosuppressive treatments in patients with non-infectious uveitis.[190] 
Induction treatment with subcutaneous daclizumab at 2 mg/kg followed by 1 mg/kg maintenance 
treatments every other week was determined to be safe. In addition, the administration of 
intravenous daclizumab for the treatment of non-infectious uveitis was explored in a long-term, 
phase I/II single armed interventional study.[191] This study provided preliminary evidence that 
regularly administered infusions of daclizumab can be given as an alternative to standard 
immunosuppressive therapies for years to treat severe uveitis.  
1.6.3.3  Anti-IL-17A  
T-helper 17 (Th17) cells are a sub-set of pro-inflammatory T helper cells and one of the main 
pathogenic effectors in autoimmune uveitis. Specifically, Th17 cells produce the pro-
inflammatory cytokine IL-17A and other effector cytokines, including IL-17F and IL-22.[192] The 
upregulation of IL-17A in patients with uveitis has led to experimental treatments specific to this 
target.[193] For instance, secukinumab (Novartis Pharma AG, Basel, Switzerland) is a selective, 
high-affinity and fully-human monoclonal antibody that binds to human IL-17A. This binding is 
thought to inhibit the expression of other pro-inflammatory cytokines and effector proteins, thus 
preventing the downstream activation of neutrophil granulocytes, macrophages, epithelial cells, 
and fibroblasts.[194] Secukinumab blocks inflammation in patients affected by psoriasis, 
rheumatoid arthritis, and uveitis.[195] Intravenous dosing of secukinumab has shown greater 
efficacy than subcutaneous dosing in patients with non-infectious uveitis, suggesting that patients 
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may not receive a sufficient amount of drug with subcutaneous administration.[196] Moreover, 
three multicenter, randomized, double-masked, phase III studies in the United States have 
examined the efficacy and safety of different doses of Secukinumab in patients with non-
infectious uveitis.[152] Although the study suggested that secukinumab administration resulted in 
a beneficial effect and allowed for reduction of the use of concomitant immunosuppressive 
medication, the authors did not discover any dissimilarities in uveitis recurrence between placebo 
groups and secukinumab treatment groups.[152] On these bases, further research may be needed to 
assess the efficacy of secukinumab in managing non-infectious uveitis in patients who are 
refractory to routine immunosuppressive treatments.  
1.6.3.4  Anti-CD28 - Abatacept  
Abatacept (Bristol-Myers Squibb, New York, NY, United States) is a fusion protein composed of 
the Fc region of the immunoglobulin IgG1 and the extracellular domain of cytotoxic T-
lymphocyte antigen 4.[197] T-cell activation involves both the T-cell receptor and a co-stimulatory 
signal provided through the binding of CD28 on the T-cell to the B7 protein on an antigen-
presenting cell such as a dendritic cell. Specifically, abatacept acts by binding to the B7 protein, 
thus preventing co-stimulatory signaling, and ultimately leading to impedance of T cell 
activation. Abatacept is currently an approved treatment for juvenile idiopathic arthritis (JIA) - 
related uveitis and rheumatoid arthritis, and can be administered either as an intravenous infusion 
or subcutaneous injection.[153,198] Several studies support the efficacy of abatacept in controlling 
or improving JIA-uveitis in children and young adults. Particularly, a study carried out on seven 
patients affected by JIA-related uveitis and refractory or intolerant to immunosuppressive 
demonstrated an improvement in all patients, although only one patient had complete remission 
over a follow-up period of 7-11 months.[199] In addition, the therapy was well tolerated in six of 
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the seven patients. Another small study performed on two patients showed that the use of 
abatacept may result in complete remission of uveitis after several months of treatment.[200] 
However, both studies involved a small sample size (seven and two respectively), and, for this 
reason, a larger series of studies and a longer term follow-up may be required to confirm the 
efficacy and cost effectiveness of this therapy.  
1.6.4 Engineering Approaches to Treat Uveitis 
1.6.4.1  Fluocinolone acetonide implants – Retisert 
Retisert (Bausch & Lomb, Rochester, NY, United States), is a non-biodegradable implant 
containing a synthetic corticosteroid, fluocinolone acetonide, and designed for a long-term, local 
release of the therapeutic agent  as represented in Figure 8. The pharmacokinetics of 
fluocinolone acetonide was initially tested in vivo in 24 rabbits receiving implants of either 0.5 
mg or 2 mg.[156,201] After the first month a constant release of the active principle was observed 
for a period of 12 months, with minimal systemic absorption as demonstrated by urine and 
plasma concentration below the detection limits.[156] Similar results were obtained in another 
study where the release rate was constant over the one-year testing period.[201] The effectiveness 
of the fluocinolone acetonide implant (releasing approximately 2  µg/day) was investigated in a 
pilot study composed of five patients with severe posterior uveitis.[202] After a ten month follow-
up, visual acuity was either improved or stabilized, and inflammation was under control in all 
patients treating with the implant.[202] Successively, in a double-blind study patients were 
randomized to receive fluocinolone acetonide intravitreal implants of 0.59 mg (0.6  µg/day) or 
2.1 mg (2  µg/day) for 58 months.[157] The outcome of the results of the study showed an 
improvement in mean visual acuity with no recurrences of ocular inflammation during the first 
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two years after implantation.[157] In 2005, Retisert was approved by the FDA for the treatment of 
chronic, non-infectious, posterior uveitis.[203,204] Retisert is an ocular the implant composed of a 
silicone elastomer containing 0.59 mg fluocinolone acetonide, which is surgically implanted in 
the posterior segment. Over the first month following implantation, the device delivers the 
medication at a rate of 0.6 µg/day, followed by a continuous delivery of 0.3-0.4  µg/day for 30 
months. The drug delivery rate depends on different factors such as surface area, permeability of 
polymers, drug solubility, and rate of drug clearance.  
 
 
 
 
 
 
 
Figure 8. (A) Schematic and (B) site of implantation of Retisert. 
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1.6.4.2  Cyclosporine-Releasing Microparticles 
As discussed previously, cyclosporine has been proven to be effective in controlling 
inflammation in patients with uveitis. However, there are limitations (low bioavailability and 
systemic side effects) associated with the commonly used formulations of cyclosporine 
(topically, systemically administered).[205,206] To overcome these limitations, microparticles 
containing cyclosporine have been under investigation as an alternative system for delivering the 
drug for a prolonged period of time, thus achieving a prolonged drug action with reduced side 
effects shown in Figure 9.[86,205] In particular, it has been demonstrated that PLGA-based 
microparticles containing cyclosporine allow for a sustained concentration of the drug in the iris-
ciliary body and choroid-retina of healthy rabbits for at least 65 days after injection shown in 
Figure 9B.[86] Moreover, the mean residence time of the drug loaded in the microparticles was 
ten times higher than cyclosporine solution.[86] Similar results have been obtained using 
cyclosporine-loaded lipid microspheres, capable of a prolonged release of the medication with 
cyclosporine concentration much higher than in the traditional ocular emulsion.[207] These results 
suggest that patients affected by uveitis could potentially benefit from the use of sustained-
release drug formulations, representing a way to localized and deliver the drug more efficiently 
than topical or systemic administration.  
 
 
 
 
 
 
45 
Figure 9. Scanning electron microscopy images (SEM) of PLGA microparticles loaded with 
cyclosporine (A) SEM image of microparticles before the in vitro release assay (B) SEM image after two 
weeks of in vitro release (C) SEM image taken after two months of in vitro release (10 m scale bar). (D) 
Diagram showing the concentration of cyclosporine released overtime in different ocular tissues and blood 
subsequently after the cyclosporine microparticles are intravitreally injected for the treatment of uveitis. () 
Iris-ciliary body; () cornea; (∆) conjunctiva; (O) aqueous humor; () blood; () vitreous body; (●) choroid-
retina; (•) sclera; (▲) lens. Reproduced with permission.[86]Copyright 2006, Association for Research in 
Vision and Ophthalmology. 
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1.6.5 Gene Therapy for Uveitis 
Although gene therapy of retinal degeneration has been under investigation in diseases such as 
AMD, it is also a new approach for uveitis, and only few studies on animal models have been 
attempted.[160] For example, an adenoviral-mediated transfer of the interleukin (IL)-10 gene for 
the inhibition of autoimmune anterior uveitis was investigated using a rat model.[158] Specifically, 
the adenoviral construct expressing IL-10 (Ad-IL-10) or carrying no cytokine transgene was 
systemically administered to the rats. The results from the study suggested that rats receiving one 
or two divided administrations of Ad-IL-10 had a reduction of leukocyte infiltration in the 
anterior chamber of the eye.  In another experimental study, a lentiviral vector was developed for 
the delivery of genes encoding murine IL-1Ra (mIL-1Ra) and murine IL-10 to the anterior 
chamber, in order to determine whether it could affect the inflammatory response.[208] A 
significant reduction in the severity of experimental uveitis was demonstrated, suggesting that 
the utilization of lentiviral-mediated expression of immunomodulatory could be promising as a 
potential, future treatment for the anterior chamber of the eye. 
 47 
1.7  DRY EYE DISEASE 
1.7.1 Background on the Pathology  
Dry eye disease affects the tears and ocular surface, afflicting more than 10 million individuals in 
the United States alone.[209–213] Epidemiological studies suggest that aging and female sex are 
two of the most common risks factors for DED.[5] Several other risk factors for this particular 
ocular condition include autoimmune diseases (rheumatoid arthritis, Sjögren’s Syndrome), 
thyroid disease, hormonal changes, and refractive laser surgery.[2] Typically, patients with one or 
more of these risks factors will also experience symptoms such as ocular irritation, dryness, tear 
hyperosmolarity, and foreign body sensation.[214,215] In severe cases, DED can lead to the risk of 
developing infections and corneal ulcerations resulting in blindness.[6] Moreover, these 
symptoms can have a significant effect on the patients’ quality of life by affecting their visual 
ability to complete daily tasks (ex: reading or driving), which may lead to psychological side 
effects such as anxiety and depression.[215] Given the surprisingly serious nature of these side 
effects, a variety of methods has been explored in an attempt to mitigate these symptoms.  
One common therapeutic strategy to help minimize the symptoms of dry eye is tear plugs (as 
described in section 1.2.3), which preserve the health of the ocular surface by conserving 
tears.[216] Plugs as shown in Figure 2 are classified by the location of insertion, which can 
include either the puncta or canaliculi (nasolacrimal drainage ducts) and plugs can be either 
permanently or temporarily inserted.[217] A factor that contributes to the intended duration of 
usage is the composition of the tear plug, which could be made of degradable collagen, gelatin, 
as well as non-degradable materials such as silicone, Teflon, and hydromethylacrylate.[216] Even 
though tear plugs are considered safe and have shown to be effective for maintaining ocular 
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lubrication, some individuals experience complications associated with plug retention rates and 
infection.[216] It also has been demonstrated that closing the puncta exposes the ocular surface to  
high levels of pro-inflammatory cytokines in the tears, which can lead to exacerbated symptoms 
of DED.[217] 
A common alternative to help lubricate the ocular surface for individuals with dry eye 
symptoms is the use of artificial tears.[218] As administered in eye-drop format, artificial tears can 
help to reduce the friction between the ocular surface and eyelids, providing relief for some (but 
not all) patients.[215] However, preservatives that are included in the formulation can result in 
hyperosmolarity of the tear film, leading to ocular surface inflammation.[215] One type of 
preservative known as benzalkonium chloride (BAK) has been speculated to cause 
hyperosmolarity of the tears, induce ocular irritation, lower cell viability, and induce oxidative 
stress on conjunctival epithelial cells in long-term treated dry eye patients.[219] Due to these 
potential side effects, new formulations have been developed that contain electrolyte-based 
artificial tear substitutes with a buffering component to help decrease the hyperosmolarity of the 
tears and aid to preserve the ocular surface.[220] 
Ultimately, although artificial tears and punctal plugs have proven to lessen various 
symptoms of DED in some patients (such as ocular irritation and discomfort), they are not 
designed to address the underlying cause of the condition.[5] More recently, the inflammatory 
response has been identified to play a prominent role in the development and propagation of 
DED.[12,14,221–223] Specifically, inflammation leads to hyperosmolarity of the tear film and, 
ultimately, tissue destruction.[215] One of the primary mediators of ocular inflammation and tissue 
destruction are pathogenic effector T lymphocytes.[6] Generally, these lymphocytes are 
associated with chronic inflammation.[224] Adoptive transfer of pathogenic CD4+ T lymphocytes 
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from mice that have induced DED into a nude mice develops DED in cell recipients.[225] Also, 
ocular inflammation is associated with increased expression of CCR5, which, in turn, results in 
the recruitment and infiltration of pathogenic effector T cells to the ocular tissue.[6,225–227] 
Building upon this evidence, current and new investigative therapeutic approaches have been 
developed to reduce ocular inflammation in order to restore the ocular microenvironment in 
DED  as shown in Table 3.[112,228,229] 
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Table 3. Summary of Dry Eye Disease Treatments. 
 
Treatment Type of Study Results Ref. 
Lipids Murine Topical administration of omega-3 fatty acids reduced corneal 
fluorescein staining and altered pro-inflammatory cytokine milieu in 
the ocular tissue. 
[111] 
 
LipiFlow Clinical  Approved in 20011 by the FDA, LipiFlow is a medical device that 
uses vectored thermal pulsation to stimulate the release of meibum. 
[113] 
[114] 
[115] 
[116] 
[117] 
 
Corticosteroids Murine This class of steroid hormones can suppress molecular stress responses 
through reducing inflammation and resolving signs of DED. 
 
[121] 
[122] 
Doxycycline Murine PLGA-based microspheres loaded with doxycycline were able to 
modulate the effects (ex: corneal fluorescein staining) of DED. 
[108] 
Cyclosporine A 
(CsA) 
Clinical Restasis©; Allergan Inc, Irvine, California is a  
cyclosporine A ophthalmic emulsion used to treat patients with chronic 
DED. 
[109] 
[124] 
 
 
Contact Lenses Rabbit In order to overcome the low bioavailability of topically administered 
drugs to the ocular surface, contact lens  
(ex: silicone based and hyaluronic acid-laden ring implants) have been 
utilized to enhance drug residence time.  
 
[28] 
[136] 
CCR2 Murine Biological immune antagonists have shown to decrease mRNA 
expression levels of cytokines and reduce the infiltration of antigen-
presenting cells to the ocular surface. 
[125] 
Lifitegrast Murine and Clinical An FDA approved integrin antagonist of LFA-1 demonstrated the 
ability to reduce ocular surface inflammation in a desiccating stress 
murine model and significantly improved ocular irritation in clinical 
trials. 
 
[107] 
[139] 
[141] 
Regulatory  
T cells 
Murine The ex vivo expansion of Tregs into a mouse with DED was able to 
resolve signs of inflammation. 
[154] 
Synthetic 
Approaches to 
Recruit Tregs 
Murine PLGA-based microspheres loaded with a chemokine, CCL22, was able 
to resolve signs of DED and shift the ratio of Tregs to effector T cells 
in the lacrimal gland tissue. 
[85] 
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1.7.2 Anti-Inflammatory Based Treatments for Dry eye Disease 
1.7.2.1  Lipids and LipiFlow  
One therapeutic strategy for DED is the administration of fatty acids such as omega-3s, which 
are known to reduce inflammation through the downstream effects on the NF-κB pathway.[230] 
Topical administration of omega-3 was explored in attempt to mitigate DED symptoms such as 
corneal fluorescein staining,[231] as an increase in corneal staining is an indicator of corneal 
disease severity.[232] Specifically, the fluorescein dye stains dead squamous epithelial cells and 
can diffuse into areas where cellular tight junctions have been compromised.[232] The results of 
the sample scoring suggest that the fluorescein staining was decreased in animals treated with 
fatty acids.[231] In addition to a reduction of corneal fluorescein staining, mRNA levels of pro-
inflammatory cytokines in the cornea and conjunctiva (e.g. IL-1 and TNF-α) were lower in 
treated animals, suggesting that omega-3 fatty acids can alter the pro-inflammatory milieu and 
lessen the signs of dry eye.[212,214,223,233]  
Other types of lipid-based treatment approaches have also been developed to mitigate the 
symptoms associated with the disease including a device known as LipiFlow  represented in 
Figure 10.[234] This particular medical device uses a 12-minute vectored thermal pulsation (VTP) 
treatment that applies heat to the eyelid while also applying pressure to the outer eyelids to 
enable the release of meibum (oil like substance found in the tears).[233,235] A clinical trial 
revealed that LipiFlow was able to improve symptoms of ocular irritation, and subsequently in 
2011, the FDA approved LipiFlow as a medical device.[236,237] Although the treatment is an 
effective therapy for some patients, it is still not widely available due to its high cost.[237] Hence, 
additional numerous topical cost-effective pharmaceutical agents are being screened as a 
potential therapy for DED.[238]  
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Figure 10. Representation of the LipiFlow Disposable. Black arrows show the Eye Cup and Lid 
Warmer. Reproduced with permission.[114] Copyright 2012, Lippincott Williams & Wilkins. 
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1.7.2.2  Corticosteroids  
Corticosteroids (glucocorticosteriods) are a class of steroid hormones widely exploited for a 
range of inflammatory and immune-based diseases.[239] A few inflammatory conditions treated 
with the administration of corticosteroids include: asthma, chronic obstructive pulmonary disease 
(COPD), uveitis, and age-related macular degeneration.[58,91,239] Corticosteroids have multiple 
methods of action to abate inflammation.[239] Classically, one prominent method of action is 
through the glucocorticoid receptor mediated pathways, which act to inhibit the synthesis of 
multiple inflammatory proteins thereby suppressing pro-inflammatory genes and lymphocyte 
activation.[239] Since inflammation and lymphocyte activation are recognized in diseases such as 
dry eye, others have examined whether glucocorticosteriods can resolve DED symptoms.[240,241] 
Several murine studies have suggested that the administration of corticosteroids can suppress 
molecular stress responses through lowering the levels of pro-inflammatory cytokines, and 
improving clinical signs of disease such as corneal fluorescein staining.[240,241] However, even 
though corticosteroids have exhibited to be efficacious for DED in short-term studies, there are 
many potential deleterious side effects associated with their long-term usage including cataracts, 
high blood pressure, increased risk of infection, and corticosteroid-induced glaucoma resulting 
from an increase of intraocular pressure (IOP).[242] Thus, in order to circumvent the potential 
long-term side effects associated with corticosteroid usage, other types of treatments have been 
examined as a therapy for patients with symptoms of dry eye.[243–245] 
1.7.2.3  Doxycycline  
Doxycycline is antibiotic classified as a tetracycline derivative used for a variety of conditions 
ranging from rosacea to cancer.[229,246] Mechanistically, doxycycline acts as a matrix 
metalloproteinase (MMP-proteolytic enzymes) inhibitor and [247] can suppress the expression of 
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pro-inflammatory cytokines.[248] In DED, it has been observed that the upregulation of several 
MMPs can result in the breakdown of tight junction protein degradation and an increase of 
epithelial desquamation to the ocular surface.[229] Due to the effects of MMPs in DED, 
doxycycline was subconjunctivally administered in order to modulate the effects of these 
proteolytic enzymes.[229] Specifically, doxycycline-loaded polymer microspheres (made from 
PLGA), that controllably release the doxycycline over time, abated the effects of desiccating 
stress induced DED in a murine model.[229] Ultimately, this investigation suggests that 
doxycycline PLGA-based microspheres resolved corneal barrier disruption in mice as compared 
to the unloaded (no drug) microspheres.[229] 
1.7.2.4  Cyclosporine A 
Cyclosporine A (CsA) is an immunosuppressive agent utilized for several inflammatory 
conditions such as organ transplantation, rheumatoid arthritis, and uveitis.[111,143,169,249] CsA 
inhibits calcineurin, (a serine/threonine phosphatase), decreasing the expression of specific genes 
that are involved in T-cell activation and the production of interleukins (IL-2), which acts as a 
lymphocyte mitogen.[250] A recent clinical trial evaluated the use of topical CsA ophthalmic 
emulsion 0.05%, for the treatment of DED (Restasis©; Allergan Inc, Irvine, California).[112] One-
hundred and fifty-eight subjects ranging in severity from mild, moderate and chronic DED were 
monitored for a period of 3-16 months, and by the end of the study, the administration of CsA 
appeared to be responsible for significant reduction in clinical symptoms of DED.[112] Notably, 
however, it can take several months for CsA to have a therapeutic effect in some patients.[251] 
Therefore, new treatments continue to be developed with the goal of achieving a more rapid 
onset of action and sustained delivery while simultaneously addressing the underlying 
inflammation mediating DED.[244,251]  
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1.7.3 Contact Lenses 
As an approach to overcome the low bioavailability of topically administered cyclosporine A, a 
silicone-based contact lens was investigated.[31] Specifically, the incorporation of vitamin E and 
cyclosporine A into a silicone-based contact lens appeared to enhance the release duration of the 
drug to more than 1-month with only utilizing 10% of vitamin E added into the lens.[31] 
However, the incorporation of vitamin E into the contact lens induced a minor alteration in the 
refractive index of the contact lens.[31] In an attempt to evade this issue, others have attempted to 
achieve sustained ophthalmic drug delivery without altering the optical properties of the contact 
lens with a new hyaluronic acid-laden ring-implant contact lens shown in Figure 11. The 
combination of the ring/implant (separation of drug to the outer rim of the lens leaving the 
central portion over the pupil unloaded) enabled the sustained delivery of the drug while 
maintaining ideal optical properties over the pupil for vision. [252] This delivery system showed 
hyaluronic acid (HA) was released in the therapeutic range for up to nine days, and the ocular 
healing was considerably faster in the rabbits treated with HA implanted contact lenses as 
compared to the untreated group.[252]  The extended release of hyaluronic acid was accomplished 
through optimizing the amount of cross linker and the thickness of the implant. 
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Figure 11. Image of a hyaluronic acid-laden implant contact lens fabricated to enable the sustained 
delivery of hyaluronic acid while maintaining ideal optical properties over the pupil for accurate vision. 
Reproduced with permission.[26] Copyright 2017, Elsevier 
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1.7.4 Biological/Small Molecule Antagonist Therapies 
1.7.4.1  CCR2  
Immune antagonists/agonists (ex: chemokine, interleukin, and ICAM-1) are a biologically-
oriented approach to halt effector T lymphocytes that can generate destructive 
inflammation.[228,244,253] One specific type of immune antagonist that has been analyzed as a 
potential treatment for DED is the chemokine receptor, CCR2 antagonist.[244] Topical 
administration of CCR2 antagonist can reduce mRNA expression levels of interleukins, IL-1α, 
IL-1β, and TNF-α in the cornea and conjunctiva, thereby affecting the pro-inflammatory 
microenvironment in the ocular tissue.[244] Furthermore, the CCR2 antagonist decreased the 
number of CD11b+ monocytes (type of antigen-presenting cell on the ocular surface) in the 
conjunctiva and cornea, which is important because antigen-presenting cells located in the 
cornea can significantly affect corneal disease pathogenesis.[209,244] Importantly, the lower levels 
of pro-inflammatory cytokine expression and cellular infiltrates in the ocular tissue contributed 
to a reduction of disease severity.[244] Despite these promising results, the administration of 
immunological antagonists may require additional investigation given the associated, serious 
side effects.[254] For example, treatment with anti-TNF-α therapy increases the patients’ chances 
of developing infections, congestive heart failure, and their overall rate of mortality.[254] Given 
this evidence, studies are needed to determine the side effects of administering a topical 
antagonist to chemokine receptors in order to determine whether this type of treatment has severe 
side effects similar to anti-TNF-α therapy.   
 58 
1.7.4.2  Lifitegrast  
Lifitegrast is an integrin antagonist (small molecule-“tetrahydroisoquinoline”) therapy that acts 
to block the binding of two cell surface proteins known as lymphocyte function-associated 
antigen (LFA-1) and intercellular adhesion molecule 1 (ICAM-1).[228] This interaction is 
essential to a number of T-cell interactions such as T-cell activation by antigen-presenting cells 
and strong adhesion to the endothelial cells during extravasation.[228,255] Due to the role of LFA-1 
in T-cell function, an antagonist of LFA-1 was investigated for the treatment of DED.[255] In a 
desiccating stress murine model, a reduction of ocular surface inflammation was observed.[256] 
Furthermore, the drug was assessed in a clinical trial of 588 masked, randomized subjects who 
either were given a placebo (control) or received topically administered Lifitegrast (5.0%) 
(Twice a day) for a period of 84 days.[257] The subjects were evaluated at days 14, 42, and 84, 
and the primary measurement of efficacy was to observe a mean change from baseline inferior 
corneal staining score (ICSS).[257] The data revealed that Lifitegrast markedly reduced corneal 
fluorescein, and improved symptoms of ocular discomfort when compared to the placebo control 
group.[257] Lifitegrast ophthalmic solution is currently approved by the FDA and is commercially 
marketed as Xiidra© (Shire Pharmaceuticals, Lexington, MA, USA).[255]  
1.7.5 Cell-Based Therapy  
1.7.5.1  Regulatory T cells 
As an alternative to blocking or suppressing T-cell mediated inflammation, it may be possible to 
take advantage of a natural mechanism the body uses to regulate inflammation.[258] In the healthy 
steady state, our bodies regulate inflammation through directing the migration of lymphocytes to 
areas of inflammation in order to resolve tissue damage and ultimately promote immune 
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regulation.[259] Within the classification of lymphocytes is a subset population of 
immunosuppressive lymphocytes known as regulatory T cells (Tregs), which are utilized by the 
body to control pathogenic effector T cells, regulating the destructive inflammation that can lead 
to tissue damage.[260–264] Disruption in the function, development or number of Tregs can lead to 
autoimmune and inflammatory diseases.[265,266] Moreover, it is now understood that an 
immunological balance of effector T cells and Tregs between the two populations is critical to 
maintain a healthy microenvironment.[265] Overall, Tregs are naturally tuned to regulate the 
proliferation of pathogenic effector T cells, and maintain immunological homeostasis in the 
ocular tissue.[267]  
Accordingly, Treg-based cell therapies have been explored (the ex vivo 
differentiation/expansion and re-implantation of live cells) for the treatment of diseases such as 
DED.[268,269] It also has been suggested that regulatory T cells (Tregs) could be harvested from 
peripheral blood, expanded ex vivo and injected back into the patient in order to boost circulating 
Treg numbers thereby reducing/resolving the destructive inflammation.[268] Such would represent 
a biologically oriented “drug” that is multi-modal, dynamic, and responsive in the local 
environment and capable of communicating to the immunological milieu. Siemasko et al. 
demonstrated that the ex vivo expansion of Tregs injected into a mouse with DED were able to 
suppress ocular surface inflammation.[270] Although adoptive transfer of Treg represents 
tremendous promise (with potential to be more effective than any “drug” while eliminating 
severe side effects), there are still several issues with the clinical translation of ex vivo expanded 
Tregs.[268] For instance, expanding sufficient numbers of Tregs can be challenging, and current 
good manufacturing practices and FDA criteria need to be maintained during ex vivo culture to 
ensure that contamination does not occur.[268] Likewise, the plasticity of Tregs causes regulatory 
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concerns, given that some Tregs may differentiate into effector T cells in situ.[268] Also, 
differentiation into effector T cells in situ can lead to an increase of abnormally high levels of IL-
2, which can result in vascular leakage syndrome, a life threating condition.[268,271] Collectively, 
there are still many hurdles to ensure safety and efficacy before being implemented as a clinical 
therapy.[268]  
1.8   CONCLUSION 
Ophthalmic drug delivery has undergone substantial transformation, with treatment strategies 
now being created that specifically address the underlying disease mechanisms. Prior to their 
application to ophthalmic pathologies, antibiotics (ex: doxycycline) and immunosuppressant 
agents (ex: rapamycin) were employed for a variety of conditions ranging from rosacea to organ 
transplantation. These drugs have now been repurposed for additional types of diseases that 
involve inflammation, which include DED, AMD and Uveitis. Newer approaches include 
targeted biologics, drug delivery systems, and gene therapies. A key element of each of these 
new methods is local delivery to the ocular tissue to halt the subsequent effects of inflammation. 
Although, these modern drug delivery systems may benefit patients that do not respond well to 
current conventional therapies, the existing regulatory guidelines make it extremely difficult to 
facilitate clinical translational of these complex therapeutic modalities. While the regulations 
concerning traditional pharmaceuticals are well established and require straightforward 
approaches that measure purity and bioactivity, new modern drug delivery therapies (ex: gene 
therapies) are far more complex from a regulatory perspective, requiring evaluation of multiple 
factors with unpredictable downstream effects. Yet new technology is consistently being 
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developed that is more specific, leading to better safety and efficacy. For example, a new 
targeted gene-editing technology is CRISPR-Cas9 (gene-based technology), which could be a 
powerful future treatment for ocular diseases since it has demonstrated promise in a preclinical 
wet AMD model.[272] In addition, modern ophthalmic therapeutic approaches are becoming more 
interdisciplinary, combining biologicals/small molecules/cells with engineered polymeric 
materials in order to create drug delivery systems that even attempt to mimic the body’s natural 
functions. As the understanding of these disease mechanisms has evolved, the body’s natural 
process of restoring homeostasis may serve as an important inspiration for the development of 
safer, targeted ocular drug delivery therapies.  
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2.0  CONTROLLED RELEASE OF TREG-RECRUTING MICROSPHERES FOR 
THE PREVENTION OF DRY EYE DISEASE 
This chapter is adapted from Michelle L. Ratay, Andrew J. Glowacki, Stephen C. Balmert, 
Abhinav P. Acharya, Julia Polat, Lawrence P. Andrews, Morgan V. Fedorchak, Joel S. Schuman, 
Dario A. A. Vignali, Steven R. Little.(2017) Treg-recruiting microspheres prevent inflammation 
in a murine model of dry eye disease. Journal of Controlled Release. 
https://doi.org/10.1016/j.jconrel.2017.05.007 
 
 
Specific Aim 1: To examine in situ recruitment of endogenous Tregs in a murine model of DED. 
 
2.1 INTRODUCTION 
 
Current/investigative modern therapeutics have been developed (ex: cells, proteins, genes etc.) 
for the treatment of inflammatory ocular diseases such as DED. However, most of these 
treatments tend to merely block inflammation rather than address the underlying immunological 
imbalance observed in DED. Specifically, the maintenance of a healthy ocular immune 
microenvironment is dependent upon an immunological balance between pro-inflammatory and 
anti-inflammatory cells.[273] Moreover, this involves the prevention of pro-inflammatory 
lymphocytes (ex: effector T cells: Th1) from infiltrating into the ocular tissue and secreting pro-
inflammatory cytokines that can directly hinder the ability of anti-inflammatory lymphocytes 
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(regulatory T cells: Tregs) to resolve the inflammation. Thus, being able to restore the 
immunological balance between pro-inflammatory and anti-inflammatory cells in the ocular 
microenvironment would represent a departure from traditional drug-based treatments. One 
potential approach to manipulate the local immunological milieu may be through enhancing the 
ratio of Tregs to effector T cells. Therefore, our efforts have been focused on increasing the ratio 
of Tregs to effector T cells, through recruiting the body’s own repertoire of Tregs to model how 
the body itself regulates inflammation and tissue destruction, and thereby ultimately preventing 
DED.[274]  
The inspiration from this approach was in fact, from a natural immunological process 
found in the body. Specifically, one particular type of protein referred to as the macrophage-
derived C-C motif chemokine ligand 22 (CCL22) is known to promote chemotactic migration of 
cells that express the corresponding chemokine receptor CCR4.[275–277] Notably, since Tregs 
express higher levels of CCR4 than other cells,[278] CCL22 can be used for preferential 
recruitment of endogenous Tregs.[279,280] Originally, Curiel et al. demonstrated that ovarian 
tumors can suppress anti-tumor immune responses, in part, by secreting CCL22 to recruit tumor-
protective Tregs.[281] Subsequent studies demonstrated that cells/tissues that are attacked by the 
immune system (e.g. islet allografts or skin melanocytes in patients with vitiligo) can be 
protected by gene therapy to attract suppressive Tregs by producing CCL22.[282,283] Additionally, 
our group previously demonstrated that an alternative method to gene therapy such as the 
sustained release of CCL22 from biodegradable polymeric poly (lactic-co-glycolic acid) (PLGA) 
microspheres (Treg-recruiting microspheres) can mimic cellular secretion and establishment of a 
gradient of CCL22 synthetically in vivo.[279,280] This leads to recruitment of Treg in situ and a 
marked reduction of symptoms in models of a disease of local, destructive inflammation 
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(periodontal disease).[279,280] Given that DED is also characterized as a disorder of local, 
destructive inflammation, we hypothesized that this approach could recruit Tregs in order to 
reduce inflammation associated with DED.  
Herein, we provide evidence that Treg recruitment, through local release of CCL22 in the 
lacrimal gland, effectively reduces inflammation in a model of DED. The findings from this 
study illustrate that the controlled release of CCL22 can influence endogenous Treg and, in turn, 
prevent destruction of ocular surface tissue. 
 
 
 
 
Figure 12. Synthesis strategy to recruit Tregs and shift T effectors and Treg balance for the 
prevention of dry eye disease. 
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2.2 MATERIALS AND METHODS 
In the following experiments, we aimed to assess the efficacy of Treg-recruiting microspheres 
for the prevention of pathological signs of DED. Moreover, we also aimed to determine whether 
the Treg-recruiting microspheres were able to shift the immunological ocular microenvironment.   
 
2.2.1 Fabrication of Microspheres 
Poly (lactic-co-glycolic) acid (PLGA) microspheres encapsulating recombinant mouse CCL22 
(R&D Systems, Minneapolis MN) were formulated utilizing a water-oil-water double emulsion 
technique. Briefly, 200 mg of Poly (D, L-lactide-co-glycolide) PLGA polymer (acid terminated, 
50:50 lactide:glycolide, molecular weight 7,000-17,000) (viscosity: 0.16-0.24 dL/g, 0.1 % (w/v) 
in chloroform) (Sigma Aldrich, St. Louis, MO) was dissolved in 4ml of dichloromethane and 
mixed via vortexing. Then 200μL of an aqueous solution containing 5 μg of recombinant mouse 
CCL22 (R&D Systems, Minneapolis, MN) and 2 mg of BSA (Sigma Aldrich, St. Louis, MO) 
with 15 mmol NaCl was pipetted into the mixture of polymer and dichloromethane (Sigma 
Aldrich, MO). The first water-in-oil emulsion was prepared by sonicating the polymer with 
CCL22 solution at 25% amplitude for a period of 10 seconds. Then the second water-oil 
emulsion was created by homogenizing (L4RT-A, Silverson) the first water-oil emulsion with 60 
mL 2% (wt. /vol) polyvinyl alcohol (molecular weight ∼25,000 g/mol, 98 mole % hydrolyzed; 
PolySciences) for a period of 60 seconds at 3,000 rpms. The homogenized solution was then 
mixed with 1% polyvinyl alcohol and placed onto a stir plate for 3 hours in order for the 
dichloromethane to evaporate. The microspheres were then collected and washed four times via 
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centrifuge with deionized water in order to remove any remaining residual polyvinyl alcohol. 
Lastly, the microspheres were placed in 5 mL of deionized water, frozen in liquid nitrogen, and 
lyophilized for 72 hours (VirTis BenchTop K freeze dryer). The microspheres were then stored 
at -20 °C until use. The overall fabrication process of the microspheres are shown below in 
Figure 13. 
Figure 13. Schematic of  the Double Emulsion Fabrication Process of PLGA Microspheres for the 
encapsulation of an aqueous protein. 
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2.2.2 Characterization of Microspheres 
The morphology of the Treg-recruiting microspheres was characterized using scanning electron 
microscopy (JEOL, JSM-6330F, Peabody, MA) and volume impedance measurements were 
performed on a Beckman Coulter Counter (Multisizer-3, Beckman Coulter, Fullerton, CA).  In 
vitro release was determined by incubating 10 mg of Treg-recruiting microspheres in 1ml of 
phosphate buffered saline (PBS) with 1% BSA, placed on a rotator at 37°C. Release media 
(supernatant) was sampled periodically. Specifically, triplicates of each release sample were 
centrifuged at 3,500 rpm at 4°C. After centrifuging 800µl of the supernant was removed and 
placed into an Eppendorf tube and then replaced by 800µl of new PBS with 1% BSA. (Leaving 
the remaining 200µl for a total volume of 1ml).  The CCL22 concentrations were quantified 
using an enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN). The 
encapsulation efficiency was completed by dissolving 10 mg of microspheres in 200µl of 
dichloromethane (DCM) (Sigma Aldrich, MI). Subsequently, 200µl of PBS was added to the 
dissolved microspheres and centrifuged. The remaining aqueous supernant was isolated and the 
concentration of protein was quantified using an enzyme-linked immunosorbent assay (ELISA) 
(R&D Systems, Minneapolis, MN). 
2.2.3 Experimental DED Model and Treatments 
Female Balb/c mice aged 6-8 weeks were used in this study. (8 mice per group) (Charles Rivers 
Laboratories, Wilmington, MA). All animal experiments were approved by the Institutional 
Animal Care and Use Committee, University of Pittsburgh. To induce DED, mice were 
anesthetized, and 10mg/ml of Concanavalin A (ConA) (Sigma Aldrich, St. Louis, MO) of saline 
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was injected (30µl) into each lacrimal gland with a 28.5 gauge needle under a dissecting 
microscope (Olympus SZX10, Waltham, MA). DED treatments included Blank (empty) or Treg-
recruiting microspheres (25 mg/ml), which were mixed with ConA or saline and injected into the 
lacrimal glands. Soluble CCL22 was injected with ConA at a concentration of (62.5ng /1ml) 
(volume of 30µl injected). For controls intended to probe the necessity of Treg action, Treg 
function was inhibited in vivo using anti-GITR (DTA-1) (BioXCell, Lebanon, NH), which was 
injected intraperitoneally (500µg per mouse) five days prior to the injection of ConA and Treg-
recruiting microspheres.     
2.2.4 Measurement of Tear Production 
Tear production was measured with phenol red cotton threads (Oasis Medical, San Dimas, CA). 
Thread was placed in the lateral canthus of the eye for a period of 60 seconds, and wetting was 
measured in millimeters using a dissecting microscope (Olympus SZX10, Waltham, MA). 
2.2.5 Corneal Permeability 
To evaluate the corneal epithelial layer, fluorescein stain (1µL of 1% solution) was applied to the 
conjunctival sac and 5µl of saline was used to wash off any excess dye. The surface of the cornea 
was evaluated using a dissecting microscope with a fluorescent excitation lamp (Olympus 
SZX10, Waltham, MA). Eyes were evaluated in a masked fashion by an independent 
ophthalmologist, and scored 0 for no staining, score 1 for a quarter of staining, score of 2 for less 
than a half, score of 3 for half, and 4 for more than half of the eye.  
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2.2.6 Histopathology 
At the end of the study, eyeballs were exenterated then harvested and fixed in formalin for 24 
hours. Eyes were sectioned 5µm thick and stained with Periodic Acid Schiff (PAS) to identify 
goblet cells in the conjunctiva. The histology section images were scanned using a Zeiss Axio 
Scan Z1 (Thornwood, NY). Numbers of goblet cells were quantified using Pannoramic Viewer 
software (3D HISTECH Ltd.) of Zeiss Axio Scanned slides at 20x. 
2.2.7  Immunophenotyping Analysis by Flow Cytometry 
Lacrimal glands, regional draining cervical lymph nodes (CLN) were harvested from the 
experimental murine groups at the end of the study, and single cell suspensions were prepared. In 
order to increase total cell counts multiple tissue samples were combined. Cells were stained 
with the following fluorescent conjugated antibodies: anti-CD4 eFluor450 (RM4-5), anti-CD25 
APC-Cy7 (PC61), anti-FoxP3 PE (FJK-16s) (eBioscience, San Diego, CA and BD Bioscience, 
San Jose, CA). For intracellular cytokine staining, the cells were placed in a 96-well plate 
overnight in cell culture media with Cell Stimulation Cocktail (plus protein transport inhibitor, 
eBioscience) and stained with anti-IFN-γ FITC (XMG 1.2) (eBioscience, San Diego, CA).  
Absolute counting beads were used for the lacrimal gland (ThermoFisher Scientific, Waltham, 
MA). Stained cells were analyzed using FlowJO (Ashland, OR).  
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2.2.8 Statistical Analysis 
Data are expressed as mean ± standard deviation. Comparisons between multiple treatment 
groups were performed using one-way ANOVA, followed by Bonferroni multiple comparisons, 
and p ≤ 0.05 was considered statistically significant. Statistical tests were performed using 
GraphPad Prism Software 6.0, San Diego, CA. 
2.3 RESULTS 
2.3.1 Characterization of Treg-recruiting Microspheres  
We first sought to engineer a Treg-recruiting MS formulation that sustained the release of the 
chemokine, CCL22 in a relatively linear fashion such that they could potentially be used to 
produce a biological gradient in vivo. A double emulsion-evaporation technique was used to 
encapsulate CCL22 (hydrophilic protein with high water solubility) into poly (lactic-co-glycolic) 
acid (PLGA-polymer, which is hydrophobic with a low water solubility and high solubility in 
dichloromethane) to produce microspheres.[279,280] Treg-recruiting MS were then characterized to 
determine size, surface morphology, and release kinetics  as shown in Figure 14. Specifically, a 
Coulter Counter was used to determine the average size of the microspheres, which were 
approximately 16µm displayed in Figure 14C. The Coulter Counter software guided the 
selection of an optimal concentration range for the sample in order to obtain a size distribution. 
Moreover, this microsphere size was designed to avoid cellular uptake by macrophages and other 
phagocytes.[284] The microspheres were also designed to contain surface pores, which ensured 
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minimal burst release of CCL22 from the system.[279] This can be accomplished through 
adjustment of the osmolality difference between the inner and outer aqueous phases as described 
previously by Jhunjhunwala et al.[279] Surface porosity was confirmed using scanning electron 
microscopy (SEM) seen in Figure 14A and 14B.[279] Additionally, an enzyme linked 
immunosorbent assay (ELISA) was performed to determine protein loading and measure release 
from the microspheres over time represented in Figure 14D. Lastly, in order to determine the 
encapsulation efficiency an ELISA was completed, and the total amount of CCL22 encapsulated 
in the microspheres was approximately 4.6 ng ± 0.5 (18.64% encapsulation efficiency). 
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Figure 14. Characterization of engineered porous microspheres loaded with the chemokine CCL22 
and blank microspheres. (A) Representative SEM image of porous blank microspheres (1000x)                     
(B) Representative SEM image of porous microspheres with CCL22 encapsulated (1000x) (C)  A 
representative particle size distribution obtained using a Coulter Counter shows the Treg-recruiting 
microspheres. (D) Release Kinetics of CCL22 (Treg-recruiting microspheres) from porous microspheres is 
shown (n=3). 
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2.3.2 Treg-recruiting microspheres Prevent Decrease in Tear Production, Corneal 
Staining, and Goblet Cell Depletion 
To assess whether Treg-recruiting microspheres could prevent clinical evaluations associated 
with DED, tear production, corneal fluorescein staining, and goblet cell density were used 
individually as outcomes.[285] Concanavalin A (ConA-T cell mitogen) served to establish DED, 
which causes T cell proliferation resulting in the clinical signs associated with DED [286]. Saline 
administration (in place of ConA) served as a negative control.[286] As expected, ConA-treated 
mice (diseased) exhibited significantly reduced tear secretion, relative to saline (non-diseased).  
In treatment groups (“treatment” here is referred to application of the formulation at the same 
time as the establishment of the disease), microspheres (0.5mg/30µl) were injected locally into 
the lacrimal gland as outlined in Figure 15. The treatment group significantly prevented tear 
production loss as compared to the diseased mice. Specifically, the wetting of thread (measured 
in millimeters) for the treatment group was 4 ± 0.3 mm. Moreover, the thread wetting for the 
diseased-with-blank-microsphere group was 3 ± 0.5 mm and the diseased was 3 ± 0.3 mm. 
Overall, blank microspheres did not worsen the signs of DED compared to the untreated, disease 
group as shown in Figure 16.  
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Figure 15. Treg-recruiting MS for preventing Dry eye Disease (DED) in mice. At Day 0, ConA and 
Treg-recruiting microspheres (MS) were injected into the lacrimal glands.   
 
 
The integrity of the corneal epithelial barrier via fluorescein staining was also examined 
as an indicator of disease severity. As seen in Figure 16, Treg-recruiting microsphere 
administration appears to maintain the integrity of the corneal epithelium. Consistent with an 
intact/undamaged cornea, no staining was observed on the corneas of the treatment group and 
non-diseased mice after instillation of fluorescein as represented in Figures 16B and 16C. The 
corneal fluorescein scoring for the diseased was 1 ± 1.3 as compared to the saline, which had an 
average staining score of 0.5 ± 0.6 and saline with blank microspheres of 0.4 ± 0.5 corneal 
fluorescein staining score. In contrast, corneal permeability is known to cause a decrease in the 
rate of fluorescein elimination in DED patients compared to healthy individuals [287]. Upon 
examination, central punctate fluorescein staining was observed on corneas of the diseased, 
diseased with blank MP treatment, and diseased with soluble CCL22 groups shown in Figure 
16C.  
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Figure 16. Treg-recruiting MS prevent DED symptoms in mice.  (A)  Phenol red thread wetting 
measured in millimeters for aqueous tear production (n = 8) shown as mean ± S.D. (B) A clinical score of the 
ocular surface staining scored on a scale of (0-4) (n = 8) show the integrity of the epithelial layer of the cornea. 
Green staining on the cornea is a positive indication of disease (n=8). * p ≤ 0.05;** p ≤ 0.01; *** p ≤ 0.001, 
**** p ≤ 0.0001. 
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Histological sections of the ocular tissue were also observed to make record of any 
differences in treated vs. untreated groups in our model of DED. After one week, eyes were 
exenterated, and the conjunctiva was stained with Periodic Acid Schiff (PAS) to identify goblet 
cells (appearing as bright purple/pink cells) interspersed throughout the stratified squamous cells 
of the conjunctiva. As a loss of goblet cell density occurs, tear film composition changes 
correlating to severity of conjunctival disease such as DED.[288] The diseased mice, with or 
without administration of blank microspheres and diseased with soluble CCL22 exhibited a 
significant decrease in goblet cell density compared to the non-diseased control group (saline and 
saline with blank microspheres. Specifically, the soluble CCL22 (bolus) was approximately       
45 ± 8 goblet cells while the diseased with blank microspheres was 41 ± 11, and diseased 36 ± 5 
total numbers of goblet cells counted in the conjunctiva. Administration of Treg-recruiting 
microspheres diminished goblet cell depletion to levels comparable of those observed in non-
diseased mice represented in Figure 17.   
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Figure 17. Treg-recruiting MS prevent reduction of goblet cell density in the conjunctiva.  
Representative images of histological sections of the eyes (20X) were examined to identify differences in the 
Treg-recruiting MS group compared to the diseased groups (100µm scale bar). Goblet cells shown are the 
pink/purple cells located in the conjunctiva labeled with arrows and the groups are shown as mean ± S.D.       
* p ≤ 0.05;** p ≤ 0.01; *** p ≤ 0.001, **** p ≤ 0.0001. 
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2.3.3 Treatment with Treg-recruiting microspheres decreases the frequency of CD4+ T 
Cells in Regional Draining Lymph Nodes 
To determine whether attenuation of DED symptoms by Treg-recruiting microspheres was due to 
local cellular changes in the regional lymphoid tissue, a phenotypic analysis was performed of T-
cell populations in the cervical lymph nodes (CLN). CLN from diseased mice exhibited a 
significantly greater percentage of CD4+ T cells compared with non-diseased mice, both with 
and without administration of blank microspheres shown in Figure 18A. In order to further 
assess phenotypic expression of CD4+ T cell population expression of the intracellular cytokine, 
IFN-γ was investigated. Accordingly, our results suggest that there is a significant difference 
between the diseased-with-blank microspheres, non-diseased, soluble CCL22 and the treatment 
group as shown in Figure 18B. Interestingly, there was also a decrease in the percentage of 
Tregs for the treatment group (as compared to diseased-with-blank microspheres), but no 
significant difference in activated T effectors and Tregs with the soluble CCL22 in the draining 
lymph nodes as compared to the treatment group shown in Figures 18C and 18D. Additionally, 
the diseased mice exhibited significantly higher levels of CD4+CD25+Foxp3- in the CLN 
compared with non-diseased mice as represented in Figure 18C; this was reduced in Treg-
recruiting microsphere groups as compared to diseased mice treated with blank microspheres.   
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Figure 18. Treg-recruiting MS suppress T effector cells in the regional draining lymph nodes. (A) 
Data from flow cytometry performed on the regional draining lymph nodes in order to examine overall CD4+ 
T cell percentages (n=8) shown as mean ± S.D. (B) IFN-γ cytokine expression was examined in the regional 
draining lymph nodes (n = 8) shown as mean ± S.D. (C)  Activated T effector percentages were analyzed using 
flow cytometry (n = 8) shown as mean ± S.D. (D) FoxP3+ Tregs analysis on the regional draining lymph nodes 
using flow cytometry (n = 8) shown as mean ± S.D. * p ≤ 0.05;** p ≤ 0.01; *** p ≤ 0.001, **** p ≤ 0.0001. 
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2.3.4 Treatment with Treg-recruiting microspheres Reduces Infiltration of CD4+ IFN-γ+ T 
cells in the Lacrimal Gland 
To determine whether Treg-recruiting microspheres alter T-cell populations in the lacrimal 
gland, lacrimal glands were harvested and flow cytometry was performed to analyze T-cell 
populations. Specifically, frequencies of pro-inflammatory CD4+ IFN-γ+ (Th1) T cells and CD4+ 
FoxP3+ Tregs were examined in the gland. We observed significantly greater proportions of IFN-
γ-producing CD4+ T cells shown in Figure 19A and significantly lower proportions of FoxP3+ 
Tregs as shown in Figure 19B in the lacrimal glands of diseased mice, diseased-with-blank 
microspheres, and soluble CCL22 as compared to the treatment group (Treg recruiting 
microspheres). Notably, the treatment group exhibited a significant reduction in the frequency of 
IFN-γ+ cells with a concomitant increase in the frequency of FoxP3+ Tregs represented in Figure 
19A and 19B, relative to untreated diseased mice. The CD4+ IFN-γ+ (Th1) T cells and CD4+ 
FoxP3+ Tregs in the treatment group were similar to the saline and saline-with- blank 
microspheres as shown in Figure 19A and 19B. Ultimately, shifts in the pro-inflammatory 
cytokine, IFN-γ+, and anti-inflammatory Treg populations contributed to a two-fold increase in 
the Treg/Th1-type ratio in the lacrimal gland of the treatment group relative to diseased, and was 
significantly higher for the soluble CCL22 and blank microspheres displayed in Figure 19C.  
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Figure 19. Treg-recruiting MS enhance anti-inflammatory responses in the lacrimal gland. (A)IFN-γ 
cytokine expression was analyzed in the lacrimal gland (n=8) shown as mean ± S.D. (B) Analysis of 
intracellular staining for Tregs  (n = 8) shown as mean ± S.D. (C) The ratio of CD4+ FoxP3+/CD4+IFN-γ+  
cells  in the lacrimal gland (n=8) shown as mean ± S.D. * p ≤ 0.05;** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001. 
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2.3.5 Administration of anti-GITR Reverses the Effect of Regulatory T-cell Recruiting 
Formulations 
To confirm that the observed suppressive effects were due to Tregs, a glucocorticoid-induced 
tumor necrosis factor receptor (GITR) agonistic antibody (Anti-GITR) was administered five 
days before injection of treatment. Anti-GITR is thought to inhibit the ability of Tregs to 
suppress other T cells (non-Tregs).[289] We compared the two groups ConA and Treg-recruiting 
microspheres with the anti-GITR. As expected, anti-GITR injected before treatment completely 
eliminated the symptom-reducing effects of Treg-recruiting microspheres, with tear production 
and punctate staining of the cornea comparable to (or a lower degree than) that of the diseased 
mice as shown in Figure 20A, 20B, 20C, and 20D. There was also a significant decrease of the 
number of goblet cells in the anti-GITR + Treg-recruiting MS as compared to the treatment 
group shown in Figures 20D and 20E. Additionally, mice treated with anti-GITR before 
treatment did display a significantly greater percentage of total CD4+ T cells as compared to the 
treatment group shown in Figure 20F. In addition, there was no significant difference of 
activated effector T cells and comparable numbers of IFN-γ+ Th1-type cells in the CLN of the 
anti-GITR + Treg-recruiting MS, relative to the diseased mice displayed in Figure 20F. 
Moreover, the lacrimal gland tissue of mice treated with anti-GITR  exhibited similar frequencies 
of CD4+ IFN-γ+ T cells, as compared to diseased mice and a significantly lower percentage of 
CD4+ FoxP3+ as compared to the Treg-recruiting MS group as shown in Figure 20G. Overall, 
the administration of anti-GITR worsened signs of disease and significantly increased Th1 cells 
in the lacrimal gland. 
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Figure 20.  Administration of anti-GITR reverses the prevention signs associated with DED by Treg-recruiting MS. (A) Quantification of 
corneal fluorescein staining shown as mean ± S.D. (B) Representative images of corneal fluorescein staining shown as mean ± S.D. (C) Aqueous tear 
production was quantified using phenol red threads  (D) Goblet cells located in the conjunctiva were counted and data is shown as mean ± S.D. (E) 
Representative histology images (20X) indicates arrows pointing to the pink/purple goblet cells  (F) Data from flow cytometry was performed on the 
regional draining lymph nodes shown as mean ± S.D. (G) Cytokine expression and Treg percentages were analyzed in the lacrimal gland shown as 
mean ± S.D. * p ≤ 0.05;** p ≤ 0.01; *** p ≤ 0.001, **** p ≤ 0.0001.
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2.4 DISCUSSION  
The objective of this experimental study was to utilize a sustained release formulation designed 
to balance destructive inflammation through the local chemotactic recruitment of Tregs and 
ultimately thereby prevent clinical signs of DED. In order to cause the chemotactic recruitment 
of Tregs, a sustained gradient of CCL22 (a molecule that binds to the T cell surface receptor, 
CCR4 inducing directional migration of Tregs) was required to promote cellular migration.[290–
292] The intended chemotactic gradient will ultimately be sensitive to the amount of concentration 
released, with higher amounts of release having the downside of saturating directional receptor 
binding and decreasing chemotaxis of leukocytes thus the gradient of the microspheres is critical 
for migration.[291] As Tregs migrate to a local area of inflammation, the immunological 
homeostatic balance is altered, resulting in the reduction of inflammation. The importance of 
maintaining this gradient for the recruitment of Tregs was demonstrated in the study, when a 
bolus injection of soluble CCL22 administered into the lacrimal gland did not prevent clinical 
signs associated with ConA-induced DED as shown in Figures 16 and 17. This may be the result 
of the rapid diffusion of the soluble CCL22 from the lacrimal gland.[290–292] Interestingly, 
however, we did observe a significant decrease in overall CD4+ T cells in the cervical lymph 
nodes (CLN) represented in Figure 18. Since soluble CCL22 injected into the lacrimal gland 
could drain to the CLN, this result may be attributed to a transient gradient-independent effects 
of CCL22 on T-cell activation in the CLN.[293] The lack of therapeutic efficacy with soluble 
CCL22, however, supports previous studies that suggest that a sustained gradient of chemokine 
(here CCL22 originating from the lacrimal gland) is required for recruitment of lymphocytes due 
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to the short in vivo half-lives of proteins and chemokines ( in some cases on the order of 30 
minutes) (here Tregs).[276,290–292,294–297] As further confirmation, we observed Treg-recruiting 
microspheres at one week remaining in the lacrimal gland when cells were counted for flow 
cytometry (data not shown), which suggests that the microspheres remain in the lacrimal gland 
and maintain a sustained gradient of CCL22 to attract Tregs to the tissue.  
In regard to the clinical signs of DED, we first investigated if the Treg-recruiting 
microspheres could preserve the health of ocular surface. Inflammation seen in DED can affect 
the integrity of the cornea, which can lead to ocular irritation and an increase risk of infections 
[298]. Therefore, in this study we examined the integrity of the cornea.[299] Our data suggest that 
there was a significant reduction of punctate staining on the corneal surface of the treatment 
group suggesting that the treatment led to maintenance of ocular surface homeostasis  shown in 
Figures 16B and 16C.[300,301] By contrast, a disruption of the ocular surface can be due to an 
unstable tear film, which can contribute to inflammation of the ocular surface environment as 
seen in the diseased, diseased with blank microspheres and soluble CCL22 group in Figures  
15B and 15C.[302] Notably, administration of Treg recruiting microspheres maintained 
significantly higher levels of tear production as compared to the diseased groups shown in 
Figure 15. This is consistent with a previous finding that suggested that a reduction of tear 
production can result in corneal epithelial defects, potentially linking these two results.[293] 
Overall, the data suggest that Treg-recruiting microspheres aid in preserving corneal health, and 
preventing the loss of tear production.  
Since goblet cells are involved in the production of mucin (a component of tear fluid) [303] 
we also investigated goblet cell density in our study. Histological sections revealed that the 
treatment was able to markedly decrease the attenuation of goblet cells displayed in Figure 16. 
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This maintenance of goblet cells may be associated with lower levels of the Th1 cytokine (IFN-
γ) secreted by effector T cells, which were lower in Treg recruiting microsphere treated mice as 
shown in Figure 18.[288,300,303] Notably, it has been suggested that altered ratios IFN-γ/ IL-13 
cytokines are associated with goblet cell loss in the gut mucosa, which could be related to loss of 
goblet cells in the conjunctiva.  
Since previous reports have suggested a correlation to the frequency of CD4+ IFN-γ+ cells 
and goblet cell density, the phenotypic expression of T cells were examined to identify the 
percentage of cells in the regional draining lymph nodes.[288,300,303] To the best of our knowledge, 
previous reports utilizing this particular model have not investigated the phenotypic expression 
of T cells in the regional draining lymph nodes, which serve as critical sites for the induction of 
ocular surface immune responses.[293,304,305] Our data suggest that the administration of ConA 
possessed a significantly greater percentage of CD4+ T cell populations in the cervical lymph 
nodes (CLN), which might be due to ConA increasing the proliferation of CD4+ T cells. [306] 
Interestingly, populations of pro-inflammatory Th1 cells in the CLN of diseased mice and 
soluble CCL22 were observed to be significantly higher than the saline and saline-with-blank-
microsphere control groups as shown in Figure 18. This is not unexpected, since mice 
challenged with ConA have been previously reported to possess an increased IFN-γ production 
[286]. Interestingly, treatment with Treg-recruiting microspheres is associated with a significant 
decrease of Th1-type cells when compared to administration of blank microspheres and soluble 
CCL22 as shown in Figure 18B. This is consistent with previous findings by our group and 
others that report how sustained local concentrations of CCL22 can decrease IFN-γ levels.[280,283] 
Moreover, Saban et al. demonstrated that the Th-1 type immune response can be induced in the 
regional lymph nodes causing ocular surface inflammation in DED.[307] Therefore, we 
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hypothesize that the recruitment of Tregs may decrease the CD4+ IFN-γ response in the CLN 
ultimately leading to the prevention of ocular surface inflammation.   
To further examine the effects of Tregs, resident T-cell populations were examined in the 
lacrimal gland.[308] Specifically, as immune cells migrate from the lymph nodes to the lacrimal 
gland, these cells secrete pro-inflammatory cytokines, perpetuating inflammation and negatively 
affecting function of the gland in DED.[309] Notably, the data suggest that the treatment with Treg 
recruiting MS decreases the percentage of CD4+ IFN-γ+ T cells and increases CD4+ FoxP3+ Treg 
populations (Foxp3 can be transiently expressed in effector T cells; however, steady Foxp3 
expression is needed  for the development of a functionally suppressive Treg phenotype),[310] 
which may prevent inflammation mediated tissue destruction.  This is consistent with other 
reports suggesting that Tregs can mediate a tissue-protective function by suppressing effector T-
cells as shown in Figure 19.[311–313] Overall, the data suggests that Treg-recruiting microspheres 
generate a favorable increase in the ratio of Tregs to pro-inflammatory IFN-γ+ Th1 cells, which 
suggests an explanation for the observations of suppressed ocular inflammation, goblet cell 
maintenance, and restored tear film production.  
Finally, in order to demonstrate that the effect observed with Treg-recruiting 
microspheres was due to Tregs suppressing ocular inflammation, an agonistic monoclonal 
antibody against GITR was utilized to inhibit the suppressive effects of Tregs on effector T 
cells.[314] Anti-GITR is thought to modulate Tregs through directly abrogating their suppressive 
function while co-stimulating other conventional T cells.[289,315] In humans, it has been suggested 
that the intensity of GITR expression on Tregs directly corresponds to the suppressive ability of 
regulatory T-cells.[316] The ability of anti-GITR to suppress Treg function and worsen 
evaluations of DED here is consistent with recent work suggesting that the upregulation of GITR 
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ligand expressed on retinal pigment epithelial cells in the eye via pro-inflammatory cytokines 
plays an integral role in ocular immunity health.[316]  Consistent with the diseased, diseased-with-
blank microspheres, and soluble CCL22 treated mice, there were also increased percentages of 
CD4+ IFN-γ+ cells, and decreases in the percentages of Tregs in the lacrimal gland of mice 
treated with the Treg-recruiting microspheres and anti-GITR. Overall, the data suggests that anti-
GITR reversed the beneficial effects of preventing clinical signs and inflammation associated 
with DED, likely by affecting the suppressive function of Tregs as shown in Figure 20.[302]  
Even though the data suggest that the Treg-recruiting microspheres were able to prevent 
signs and reduce inflammation in DED, there are several limitations of this particular study of 
note. For instance, the double-emulsion fabrication technique utilized can result in protein 
denaturation in the water/oil interface, which may explain the low encapsulation efficiency and 
potential protein damage that was not able to be detected using an ELISA.[317] Although, the 
double emulsion technique is well established and has been utilized in many reports to 
encapsulate proteins, other techniques have shown to increase encapsulation efficiency and 
protein activity.[318] Future work could include fabricating the microspheres with an alternative 
process by Reinhold et al. that does not result in some protein damage and can enhance the 
encapsulation efficiency of the protein.[319] Additionally, we may need to examine residual 
polymer accumulation by examining histological sections of the tissue in order to identify 
whether the biodegradation of PLGA over time could potentially cause granulation of tissue 
development.[284] Future work should be geared toward examining this potential polymer 
accumulation and confirm that the recruitment of Tregs to the lacrimal gland can overcome pre-
established inflammation. We hypothesize that, if optimized, Treg-recruiting formulations could 
be effective as a potential therapeutic since it has been previously demonstrated that Tregs 
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indeed play an integral role in resolving established inflammation associated with DED.[320] One 
particular point of focus could be the ability of recruited Tregs to overcome any pre-existing 
ocular surface tissue destruction, which may serve to catalyze inflammation and disease.[321,322] 
However, and notably, our previous data using Treg-recruiting microspheres in a murine model 
of periodontitis started a pronounced reversal of the characteristic destructive tissue 
microenvironment towards expression of markers that would best characterize a regenerative 
microenvironment.[280] Ultimately, however, further studies would be required to determine if the 
same shift in expression in the ocular microenvironment would result from treatment with Treg-
recruiting formulations. It is also important to consider the method of administration for any 
potential therapeutic strategy. Although, injections (such as the ones into the lacrimal glands 
used herein) could be applicable given that injections in the eye and lacrimal gland have become 
more common in clinical studies and treatments [323–326], less invasive strategies (which are still 
effective) would (all things being equal) be more attractive.[327,328]    
In summary, in this chapter, our study collectively suggests that the administration of 
Treg-recruiting microspheres effectively prevents destructive inflammation in an experimental 
murine model of DED. Specifically, the sustained release of the chemokine CCL22 in the 
lacrimal gland prevented a loss of tear production, corneal fluorescein staining and goblet cell 
depletion, which resulted in the decrease of signs associated with DED. This resolution of 
inflammation and signs of DED is likely due to the increase of Tregs and decrease of Th1 cells in 
the lacrimal gland. Future studies will focus upon extending this proof-in-principle toward 
exploration of therapeutics that recruit the body’s own endogenous Tregs to resolve 
inflammation in DED. 
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3.0  TRI MICROSPHERES PREVENT KEY SIGNS OF DRY EYE DISEASE IN A 
MURINE, INFLAMMATORY MODEL  
This chapter is adapted from: Michelle L. Ratay, Stephen C. Balmert, Abhinav P. Acharya, 
Ashlee C. Greene, Thiagarajan Meyyappan, and Steven R. Little. (2017). (Submitted to Scientific 
Reports) 
 
Specific Aim 2: To explore induction of Tregs as an alternative treatment for DED.  
 
3.1 INTRODUCTION 
In the previous chapter, we discussed a biomimetic approach to locally recruit Tregs to the 
lacrimal gland utilizing the controlled release of CCL22 (chemokine) to restore immunological 
homeostasis and ultimately prevent clinical signs of DED.[329] Notably, however, Tregs can 
represent low total numbers of T-cells in the periphery, which could possibly make it non-trivial 
to achieve enough functional Treg to shift the homeostatic balance.[330] For this reason, we 
hypothesized that inducing (differentiating) Tregs from a more prevalent, naïve CD4+ population 
could also be a viable strategy that was worth exploring. Specifically, prevalent, naïve CD4+ T 
cell populations in the periphery are capable of differentiating into functional Tregs under the 
direction of a subset of antigen presenting cells known as tolerogenic dendritic cells (tDCs).53 
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tDCs induce differentiation of naïve CD4+ T cells into Tregs (in part) through the secretion of a 
combination of IL-2 and TGF-β cytokines.[331,332] However, the maintenance of Tregs is 
somewhat more complex and depends on a local microenvironment that is not only favorable to 
differentiation of Tregs, but also unfavorable to differentiation into other effector T cells.[333]  
One method of creating such a local microenvironment is through administration of the small 
molecule, rapamycin. Rapamycin (Rapa) is an mTOR inhibitor that can suppress the generation 
and proliferation of effector T cells.[334] We have previously demonstrated that sustaining the 
presence of TGF-β, Rapamycin and IL-2 using degradable microspheres was able to 
induce/differentiate naïve CD4+ T cells into FoxP3+ Tregs in vitro with high efficiency as 
represented in Figure 21.[334] 
Here we describe the in vivo application of T-Reg Inducing (TRI) microspheres (MS) in a 
model of murine dry eye disease.  Data suggests that this drug-delivery strategy can influence 
local Treg numbers and, in turn, prevent key signs of DED. Application of this new strategy 
could provide a potential avenue for new types of  immune based treatments for DED that 
influence the body’s own cells to address destructive inflammation.[335,336] 
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Figure 21. Microspheres that release a combination of recombinant proteins and a synthetic drug in 
order to promote Treg differentiation. 
 
 
 
3.2 MATERIALS AND METHODS  
TRI microspheres were fabricated as a controlled release system to promote the induction of 
naïve CD4+ T cells found in the periphery into Tregs. Subsequently, we investigated whether this 
preventative therapeutic method could shift of the pro-inflammatory microenvironment of the 
lacrimal gland and ultimately prevent clinical signs of DED. 
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3.2.1 Fabrication of Microspheres 
TGF-β and IL-2 microspheres were fabricated using a double emulsion- evaporation technique. 
For the TGF-β microspheres, Poly (lactic-co-glycolic) acid (PLGA-50:50 lactide:glycolide, acid 
terminated) (MW:7,000-17,000) (viscosity: 0.16-0.24 dL/g, 0.1 % (w/v) in chloroform) (Sigma 
Aldrich, MO) and PEG-PLGA (PolySciTech, IN) was used to encapsulate rh-TGF-β (PeproTech, 
NJ).  Specifically, 170 mg of PLGA and 30 mg of PEG-PLGA was dissolved in 4ml of DCM 
(Sigma Aldrich, MO). Then 200 µl of aqueous solution containing 10 µg of rh-TGF-β was added 
to the polymer DCM mixture. The mixture was sonicated using a sonicator (Vibra-Cell, Newton, 
CT) for 10 sec. at 25% amplitude.  Next, this emulsion was then mixed with 60 ml of 2% 
polyvinyl-alcohol (PVA, MW ~25,000, 98% hydrolyzed; PolySciences) and homogenized 
(L4RT-A, Silverson, procured through Fisher Scientific) at 3,000 rpm for 1 min. The 
homogenized mixtures were then added to 80 ml of 1% PVA on stir plate and left for 3 hours in 
order for the DCM to evaporate. After three hours, the microparticles were centrifuged (200 g, 5 
min, 4 °C), washed five times with deionized water, and lyophilized for 48 hours (Virtis 
Benchtop K freeze dryer, Gardiner, NY).  
For the IL-2 microspheres, 200 mg of PLGA (PLGA-50:50 lactide:glycolide, acid 
terminated) (MW:7,000-17,000) (viscosity: 0.16-0.24 dL/g, 0.1 % (w/v) in chloroform) (Sigma, 
Aldrich, MI) was dissolved in 4ml of DCM. Subsequently, 5 µg of IL-2 and 150 µl (R&D 
Systems, Minneapolis MN) of deionized water was added to the organic phase. Next, the two 
phases were emulsified using a sonicator probe (Vibra-Cell, Newton, CT) at 25% amplitude for a 
period of 25 seconds.  Then this emulsion was mixed with 60 ml of 2% polyvinyl-alcohol (PVA, 
MW ~25,000, 98% hydrolyzed; Polysciences) with 51.66 millimoles of NaCl and homogenized 
(L4RT-A, Silverson, procured through Fisher Scientific) at 3,000 rpm for 1 min. This secondary 
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emulsion was then then added to 80 ml of 1% PVA on stir plate and stirred for 3 hours. After 
finishing stirring, the microparticles were centrifuged (200 g, 5 min, 4 °C), washed 5 times with 
deionized water, and lyophilized for 48 hours (Virtis Benchtop K freeze dryer, Gardiner, NY). 
The rapamycin (rapa) microspheres were fabricated using a single emulsion-evaporation 
technique due to the hydrophobic nature. Rapamycin (Sigma Aldrich, MO) was dissolved in 
DMSO (Sigma, Aldrich, MO) at 10mg/ml. Then 200 mg of PLGA (Sigma Aldrich, MI) was 
dissolved in 4 ml of DCM.  Next, 100 µl of rapamycin (10mg/ml) was added to the 
polymer/DCM mixture.  The solution was then homogenized with 60 ml of 2% PVA at 3,000 
rpm for 1 min. After homogenizing, the emulsion was then added to 80 ml of 1% PVA and 
stirred for 3 hours. At the end of stirring, microspheres were washed 5 times with deionized 
water and lyophilized for 48 hours.  
3.2.2 Characterization of  Microspheres  
The morphology of the microspheres were characterized using scanning electron microscopy 
(JEOL, JSM-6330F, Peabody, MA) and volume impedance measurements were performed on a 
Beckman Coulter Counter (Multisizer-3, Beckman Coulter, Fullerton, CA). The release assay of 
the IL-2, TGF-β, and rapamycin was completed by incubating 10 mg of microspheres in 1ml of 
phosphate buffered saline (PBS) and 1% BSA, which was placed onto a rotator at 37°C. The 
supernant was sampled at different time intervals and the TGF-β and IL-2 release profiles were 
quantified using an enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, 
MN). The release profile of rapamycin microspheres was determined using UV-vis spectroscopy, 
and the release media contained 0.2% Tween-80 in PBS (absorbance at 278 nm). 
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3.2.3 Mice 
Female Balb/c mice aged 6-8 weeks were used in this experimental study. (Charles Rivers 
Laboratories, Wilmington, MA). The Institutional Animal Care and Use Committee, University 
of Pittsburgh approved all murine experiments. All methods were performed in accordance with 
the relevant guidelines and regulations. 
3.2.4 Murine DED Model and Treatment 
Dry eye disease was induced using 10 mg/ml of Concanavalin A (ConA) (Sigma Aldrich, St. 
Louis, MO) in phosphate buffered saline solution (PBS) was injected into the lacrimal glands 
with a 28.5 gauge needle using a dissecting microscope.[222,337] The controls for examining the 
effects of the TRI MS included Blank (unloaded) or TRI MS (25 mg/ml), which were combined 
with a PBS solution of ConA (10mg/ml). (Olympus SZX10, Waltham, MA).  
3.2.5 Suppression of Tregs via the Administration of Anti-GITR 
In order to identify the role of Tregs with the administration of our preventative treatment, the 
function of Tregs were inhibited using anti-GITR (DTA-1) (BioXCell, Lebanon, NH) via an 
intraparietal injection of (500 µg per mouse) 1 day after injecting the ConA and TRI MS.[280]   
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3.2.6 Tear Production 
 Phenol red cotton threads were utilized to measure tear production. (Oasis Medical, San Dimas, 
CA). The thread was placed in the lateral canthus of the eye for a period of 60 seconds, and the 
amount of wetting on the thread was measured using a dissecting microscope (Olympus SZX10, 
Waltham, MA).[222] 
3.2.7 Corneal Fluorescein Staining 
Fluorescein stain (1% solution) was applied to the conjunctival sac. The surface of the cornea 
was examined using a dissecting microscope (Olympus SZX10, Waltham, MA). The scoring of 
staining was completed by a masked ophthalmologist, and scored 0 for no staining, score 1 for a 
quarter of staining, score of 2 for less than a half, score of 3 for half, and 4 for more than half of 
the eye.  
3.2.8 Ocular Histology 
 At the conclusion of the study, the eyes were exenterated and fixed in 10% neutral buffered 
formalin.  Sections were prepared at approximately 5µm and stained with Periodic Acid Schiff 
(PAS) in order to examine goblet cell density. Histological sections were scanned and quantified 
using a Zeiss Axio Scan. Z1 (Thornwood, NY) and Pannoramic Viewer software (3D HISTECH 
Ltd.).  
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3.2.9 qRT-PCR 
Total RNA was extracted from excised lacrimal glands using TRI-reagent (Molecular Research 
Center, Cincinnati, OH), and quantified using a NanoDrop 2000 (Thermo Scientific).  For the 
reverse transcriptase assay, 2 μg RNA was converted to cDNA using a QuantiTect Reverse 
Transcription Kit (Qiagen, Valencia, CA). Quantitative real-time PCR was then performed using 
VeriQuest Probe qPCR Mastermix (Affymetrix, Santa Clara, CA), (Thermo Scientific) specific 
for (IFN-γ:Mm01168134_m1, FAM-MGB dye), (IL-2:Mm00434256_m1, FAM-MGB dye), (IL-
6:Mm00446190_ml, FAM-MGB dye), and (Gusb: Mm01197698_m1, VIC-MGB PL dye, 
endogenous control).  Duplex reactions (target gene + GUSB) were run and analyzed on a 
StepOnePlus Real-Time PCR System (Applied Biosystems, Carlsbad, CA). Relative fold 
changes of IFN-γ, IL-6 and IL-2 expression were calculated and normalized based upon the   
2-ΔΔCt method, with the Saline group as the untreated control.  
3.2.10 Immunofluorescence of the Lacrimal Gland  
At the end of the study, lacrimal glands were excised from the mice. Lacrimal glands were fixed 
with 4% PFA overnight, followed by cryoprotection through incubation in 30% sucrose 
overnight, and lastly embedded in O.C.T. medium. The cyrosections were obtained at 7μm thick 
and stained with fluorescent antibodies. Specifically, 7μm sections were blocked with 5% normal 
donkey serum and 1% Tween20 in PBS. Blocked sections were incubated overnight at 4°C with 
rat anti-FoxP3 (FJK-16s; eBio) and rabbit anti-CD3 (SP7, monoclonal rabbit IgG; Abcam, 
Cambridge, MA). The sections were then incubated with a secondary antibody, Alexa Fluor 594 
donkey anti-rat IgG (ThermoFisher Scientific Waltham, MA) and Alexa Fluor 647 donkey anti-
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rabbit IgG (Jackson ImmunoResearch Laboratories, West Grove, PA) for 1 hour at room 
temperature and then mounted using Fluoroshield mounting medium with DAPI (Abcam, 
Cambridge, MA).  The images were captured using a Zeiss Axio Scanner Z.1. Only positively 
stained cells overlapping DAPI (nuclei) were quantified. 
3.2.11 Statistical Analysis 
Data expressed as mean ± S.D.  Comparisons between multiple treatment groups were performed 
using one-way ANOVA, followed by Bonferroni multiple comparisons, and p ≤ 0.05 was 
considered statistically significant. The PCR data expressed as mean ± SEM was analyzed 
utilizing a t-test with Welch correction, and p ≤ 0.05 was considered statistically significant.  
Statistical tests were performed using GraphPad Prism Software 6.0 (GraphPad Prism, San 
Diego, CA). 
3.3 RESULTS 
 
3.3.1 Characterization of TRI MS: IL-2, TGF-β1 and Rapamycin 
TGF-β microspheres (MS) were reformulated to eliminate the 20-day initial lag phase of release 
in the prior formulation. The new formulation of TGF-β MS contains a PEG-PLGA diblock 
copolymer (4 wt%, Mn ~5 kDa), which accelerated release by increasing matrix swelling, and 
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the ester-terminated PLGA helped to minimize the electrostatic interactions between the PLGA 
polymer and the positively charged protein.[338] After measuring the release of TGF-β, the 
surface morphology of the microspheres was characterized using scanning electron microscopy 
(SEM). The representative SEM images indicate that the rapamycin and IL-2 MS possessed 
similar surface morphology and release behavior as previously reported and shown in         
Figure 22.[334] SEM images reveal spherical non-porous PLGA-based rapamycin microspheres 
represented in Figure 22. IL-2 MS exhibit surface porosity and a high initial burst followed by a 
slow continuous release for the length of the experimental study, as previously described  and 
shown in Figure 22.[334] The newly fabricated TGF-β microspheres contained an uneven surface 
morphology, similar to a previous report utilizing PEG and PLGA microcapsules.[339] The 
average size of TRI MS was 12 µm (rapamycin), 19 µm (IL-2), and 17 µm (TGF-β) as 
determined by Coulter Counter (volume impedance method).  
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Figure 22. Characterization of Treg-inducing Microspheres. (A) Representative Scanning electron 
microscopy (SEM) image of Rapamycin microspheres (1000x) (B) Representative SEM image of IL-2 
Microspheres (1000x) (C) Representative image of TGF-β Microspheres. (D) Release Kinetics of Rapamycin 
Microspheres is shown (n=3) (E) Release Kinetics of porous IL-2 Microspheres (n=3) (F) Release Kinetics of 
TGF-β Microspheres (n=3). (G)Size distribution of Rapamycin Microspheres (H) Size distribution of IL-2 
Microspheres (I) Size Distribution of TGF-β Microspheres 
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3.3.2 TRI MS Prevent Loss of Aqueous Tear Production 
To investigate whether TRI MS were capable of preventing key signs of dry eye disease, we first 
examined aqueous tear secretion.[222] Concanavalin A (ConA) was injected into the lacrimal 
gland to induce DED, and for TRI MS or Blank MS treatment groups, MS were incorporated in 
ConA injections  as shown below in Figure 23. One week following the administration of ConA 
with either Blank MS or TRI MS, phenol red thread testing was performed to evaluate tear 
secretion. The administration of ConA alone (diseased) significantly reduced tear production as 
compared to an injection of Saline (non-diseased) as shown in Figure 24A. Notably, tear 
secretion was restored to non-diseased levels in DED mice treated with TRI MS, while 
administration of  ConA + Blank MS (unloaded) had no noticeable effect on tear production in 
mice Figure 24A. In order to identify whether all three factors (TRI MS) were required to 
prevent loss of aqueous tear production, mice were treated with individual microsphere 
formulations alone (Rapa, TGF-β, or IL-2) or combinations of two microsphere formulations 
(Rapa + TGF-β; Rapa + IL-2; TGF-β + IL-2). Notably, the individual microspheres alone and the 
combinations of two microsphere formulations were unable to restore tear production inhibited 
by ConA as shown in Figure 27, suggesting that therapeutic efficacy required the delivery of the 
TRI MS to prevent the loss of tear production.  
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Figure 23. TRI microspheres for the prevention of inflammation associated with Dry eye Disease 
(DED) in mice.  A timeline for the experimental murine model of inflammation induce via Concanavalin A. 
 
3.3.3 Goblet Cell Density Maintained with the Administration of TRI MS 
Mucin is a key component associated with a healthy tear film, which is produced by goblet cells 
located in the conjunctiva.[303,340] As the density of goblet cells are diminished this can contribute 
to an unstable tear film and lead to ocular surface destruction.[340] Upon examination of ocular 
tissue histology, we observed a significant decrease in the density of Periodic Acid Schiff (PAS)-
stained goblet cells (pink/purple cells in conjunctiva epithelium layer) in the ConA group as 
compared to the Saline group as shown below in Figure 24B and 24C.[222,301,303,337,341] Treatment 
with TRI MS led to maintenance of goblet cell density, unlike mice with ConA-induced DED 
displayed in Figure 24B. Overall, histological sections revealed that TRI MS treatment markedly 
inhibited ConA-induced attenuation of goblet cells Figure 24 and 25. 
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Figure 24. TRI MS prevent clinical signs of inflammation associated with DED. (A) Wetting of phenol 
red threads were measured in millimeters using a dissecting microscope (n=6) shown as mean ± S.D. 
(B) Representative images of histological sections of the eyes (20X) were quantified to identify differences in 
the TRI MS group compared to the diseased groups and non-diseased group (100µm scale bar).  (C) Goblet 
cells shown are the pink/purple (Periodic Acid Schiff stained) cells located in the conjunctiva labeled with 
arrows and the groups are shown as mean ± S.D.  * p ≤ .5;** p ≤ .1; *** p ≤ .1, **** p ≤ .1. 
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Figure 25. Single factors (Rapamycin; IL-2; TGF-β) and combinations of two factors      
(Rapa + TGF-β; Rapa + IL-2; TGF-β + IL-2) were utilized to examine goblet cell density in the conjunctiva.       
(A) Representative images of single and combination factors of PAS stained goblet cells in the conjunctiva
(B) Quantification of goblet cell numbers from the histology of the conjunctiva
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3.3.4 Corneal Fluorescein Staining Reduced with TRI MS 
To determine the health of the ocular surface, corneal fluorescein staining was performed, with 
the degree of punctate staining as an indicator of disease severity.[342]  Fluorescent images of the 
ocular surface were captured and scored by a masked ophthalmologist on a scale of 0 to 4, with 0 
corresponding to no staining, and 4 corresponding to staining on more than 50% of the cornea, as 
seen in Figure 26A. The ocular staining score was significantly lower for the Saline and TRI MS 
groups as compared to the ConA + Blank MS group as shown below in Figure 26B. We also 
examined eyes from mice treated with ConA plus individual microsphere formulations alone or 
combinations of two microspheres. Neither individual microspheres alone and combinations of 
two microsphere formulations, were able to reduce corneal fluorescein staining to the same 
extent as the TRI MS treatment as shown in Figure 27, suggesting that local administration of 
TRI MS is necessary to restore ocular surface health that is impaired by ConA. 
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Figure 26. TRI MS reduce ocular surface staining. (A) Representative images of corneal fluorescein 
staining. (B) Clinical corneal fluorescein staining scores of the ocular surface on a scale of (0-4) (n = 6) shown 
as mean ± S.D.  * p ≤ .5 
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Figure 27. (A) Phenol Red Thread testing for the single factor (Rapamycin; IL-2; TGF-β) and 
combination of two factors (Rapa + TGF-β; Rapa + IL-2; TGF-β + IL-2) experimental groups. (n=6) (B) 
Ocular Surface Staining score (n=6) (C) Representative images of corneal fluorescein staining 
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3.3.5 TRI MS Decrease Pro-Inflammatory Cytokines 
Several cytokines in the local milieu of the lacrimal glands were examined following treatment. 
Notably, while ConA induced expression of pro-inflammatory IFN-γ, IL-6, and IL-2 in the 
lacrimal gland  as shown in Figure 28, TRI MS treatment significantly reduced expression of 
each of these cytokines, compared to the administration of ConA alone as shown below in 
Figure 28.[222,337] The relative expression of pro-inflammatory cytokines in the lacrimal glands 
can be correlated with infiltration of CD3+ T cells, which was increased in the ConA + Blank MS 
group and reduced with TRI MS treatment shown in Figure 29.[286] Together these data indicate 
that the TRI MS treatment was able to reduce the ConA-induced expression of pro-inflammatory 
cytokines in the lacrimal gland tissue. 
Figure 28. Administration of TRI MS reduces levels of cytokines in the lacrimal gland shown as 
mean ± SEM * p ≤ 0.05 
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3.3.6 TRI MS Increase the Percentage of FoxP3+ Tregs of overall CD3+ T cells in the 
Lacrimal Gland  
In order to examine the local immune environment of T-cells in the lacrimal gland, we 
performed immunofluorescence staining of lacrimal gland sections with anti-CD3 and anti-
FoxP3 monoclonal antibodies. While there were fewer total numbers of infiltrating CD3+ T cells 
with TRI MS treatment, there was a larger ratio of those FoxP3+ Tregs of overall CD3+ T cells, 
compared to the ConA alone and ConA + Blank MS groups as represented in Figure 29.  
Collectively, this data suggest that the sustained delivery of TRI MS is capable of locally 
enriching Treg populations as compared to effector T cells in the lacrimal gland tissue.   
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Figure 29. Representative lacrimal gland fixed frozen cryosections (10X magnification) stained for T-
cells (CD3+ T cells-Cyan), Regulatory T-cells (FoxP3+ T cells - Red), and nuclei (DAPI-blue). Scale bars are 
100μm. Quantification of lacrimal gland T cells per imaged field and % Treg, based on IHC images with 
FoxP3 staining (n=5).  * p ≤ 0.05;** p ≤ 0.01; *** p ≤ 0.001 
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3.3.7 Suppression of Tregs via Administration of Anti-GITR 
An agonistic antibody (DTA-1) specific for GITR (glucocorticoid tumor necrosis factor) was 
administered 1 day after the injection of the ConA and TRI MS to determine whether the 
prevention of  dry eye symptoms are mediated by the expanded Treg population.[314] Monoclonal 
antibody anti-GITR (DTA-1) acts to systemically attenuate the suppressive function of Tregs by 
inhibiting the ability of conventional T cells to be suppressed by Tregs.[289,315,343] Mice were 
administered anti-GITR, one day after ConA and TRI MS. The anti-GITR group (with TRI MP 
administration) exhibited restored pathological features of DED as indicated by the decrease of 
aqueous tear secretion as shown in Figure 21A, reduction of goblet cells in the conjunctiva as 
shown above in Figure 21B and 21E, an increase of fluorescein staining as shown in          
Figure 22C and 22D as compared to the TRI MS group without anti-GITR. Moreover, with the 
administration of anti-GITR, expression of pro-inflammatory cytokines were significantly 
increased in the lacrimal gland as compared to the TRI MS with no anti-GITR as shown in 
Figure 28.  
 
 
 
 
 
 
 
 
 
 112 
3.4 DISCUSSION 
A number of investigations have demonstrated that DED is thought to be mediated by CD4+ T 
cells.[298,304,344–346] Moreover, hallmarks of CD4+ T cell-mediated inflammation associated with 
DED include epithelial apoptosis, abnormal tear film composition and an increase of pro-
inflammatory cytokines within the ocular tissue.[305,347] Typically, one the first features DED 
patients recognize as a symptoms is ocular dryness due to a reduction in tears (abnormal tear film 
composition), which can lead to a decrease of visual acuity.[340,348] Within the tears there are 
three main components that support the ocular surface; water, mucin, and lipid.[349] All of these 
three components play an integral role in lubricating the ocular surface and maintaining 
health.[350] As ocular dryness ensues, a lack of lubrication and epithelial surface protection can 
result.[351] Due to the integral role tears play in maintaining a healthy ocular surface, tear 
secretion was evaluated to determine whether the preventative treatment (TRI MS) decreased 
tear loss thereby subsequently preserving ocular lubrication. Our data suggest there was a 
significant reduction of tears in the ConA alone as compared to the Saline as shown in Figure 
24, as expected.[222,329,337] Notably, the TRI MS significantly prevented the reduction of tears as 
compared to the ConA alone group shown above in Figure 24. However, when either the 
individual microsphere formulations alone (Rapa, TGF-β, IL-2) or the combination of two 
microsphere formulations (Rapa + TGF-β; Rapa + IL-2; TGF-β + IL-2) were administered, there 
was no significant restoration of tear production observed as shown in Figure 27. These data 
suggest the combination of all three factors (TRI MS) are required to achieve prevention of tear 
loss.  
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In addition to tear production, we also investigated the effects of the treatment on goblet 
cells, which produce the tear film (mucin); [285] a key component  that provides a protective and 
stabilizing function for the ocular surface.[352] The histological sections of the eye tissue were 
examined to identify if goblet cells were preserved with the administration of TRI MS. Notably, 
there was a significant preservation of goblet cells in the TRI MS group as compared to the 
ConA alone and ConA + Blank MS groups as shown in Figure 21. This may be due to reduced 
expression of IFN-γ in lacrimal glands of mice treated with TRI MS, compared to the ConA 
alone treated mice as shown in Figure 28. Specifically, an increase expression of IFN-γ has been 
attributed to the sustained proliferation of CD4+ effector T cells (Th1 cells).[305,344] For example, 
mice with DED exhibit increased frequencies of the pro-inflammatory Th1 cytokine IFN-γ, 
which can infiltrate the conjunctiva, causing a reduction of goblet cells.[353] Notably, previously 
published data suggest that the overall number of goblet cells were not affected in IFN-γ knock 
out mice with DED, demonstrating the potential specific involvement of IFN-γ in DED 
pathogenesis.[288] Indeed, the protective effects of TRI MS may be a result of reduced infiltrating 
Th1 cells in general, or a reduction in IFN-γ specifically as shown in  Figure 28.[347]  
As goblet cells undergo apoptosis, potentially due to IFN-γ, the composition of the tear 
film can become abnormal, which may lead to a disruption of the corneal epithelial tissue.[351] 
For this reason, an ocular staining test was performed to determine if the reductions in tear 
secretion and goblet cell density corresponded to an increase of corneal fluorescein staining.[354] 
Specifically, the increase in corneal staining may be due to the fluorescein dye remaining in 
areas left by desquamated epithelial cells.[354] As expected, corneas from the ConA alone and 
ConA + Blank MS groups showed a significant increase of corneal fluorescein staining 
compared to the Saline and TRI MS groups  as shown in Figure 26.  
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Previous reports have shown that a potential explanation for the reduction of fluorescein 
staining may be reduced levels of pro-inflammatory cytokines.[298,355] To investigate whether the 
reduction in corneal epithelial destruction in our studies corresponded with a decrease in pro-
inflammatory cytokines, qRT-PCR was performed on the lacrimal gland tissue to detect changes 
in expression of IL-2, IL-6 and IFN-γ. In addition to the better-known inflammatory function of 
IL-2 and IFN-γ, there has been observed increases of the pro-inflammatory cytokine IL-6 in dry 
eye patients.[298] As expected, IL-2 and IFN-γ levels were significantly decreased in the TRI MS 
as compared to the ConA alone and ConA + Blank MS groups, which may be due to TRI MS 
mitigating the effects of ConA causing inflammation.[337,356] A decrease of IL-6 expression levels 
was also detected in the TRI MS as compared to ConA alone group. Overall, there was a 
significant difference between the ConA alone and ConA + Blank MS and TRI MS groups levels 
of pro-inflammatory cytokines within the lacrimal gland. These results likely correlate to the 
observed decrease of CD3+ T cells in the TRI MS as compared to the ConA alone group  as 
shown in Figure 29.  
If the shift in the pro-inflammatory milieu of the ocular tissue was a result of the TRI MS 
expanding the expression of FoxP3+, then it would be expected that there would be a greater 
number of Tregs (or at least an increase in the ratio of Treg-to-effector T-cells) in the lacrimal 
gland tissue. Accordingly, immunofluorescent staining of total CD3+ T cells and FoxP3+ Tregs 
was performed on the lacrimal gland tissue. We indeed observed a significant increase in total 
numbers of CD3+ T cells in the lacrimal glands of ConA alone and ConA + Blank MS groups, as 
compared to the Saline and TRI MS groups as shown in Figure 29. We also observed a 
significant increase in the ratio of Treg-to-effector T-cells in the TRI MS as compared to the 
ConA alone and ConA + Blank MS groups as shown in Figure 29, supporting the hypothesis 
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that TRI MS are expanding the percentage of Tregs to overall CD3+ T cells. To further test 
whether TRI MS were preventing signs of DED through the expansion of Tregs, anti-GITR was 
administered to impair Treg function.[289] We observed that anti-GITR reversed the beneficial 
effects of the TRI MS as shown above in Figures 21A,21B, 21C, and 22B potentially indicating 
that Tregs are needed to mediate the therapeutic effects of TRI MS treatment.  Although, the 
current study demonstrates prevention of DED in an experimental murine model, future studies 
will need to evaluate this drug-delivery system as a treatment for pre-existing DED, and test TRI 
MS efficacy in a pre-clinical larger animal model such as rabbits. 
 In conclusion, the present study suggests TRI MS were able to reduce the local pro-
inflammatory milieu of the lacrimal gland tissue. TRI MS prevented tear loss, preserved goblet 
cell density and reduced corneal fluorescein staining, which indicate that the therapy prevented 
signs of DED. Importantly, TRI MS were able to decrease the total number of CD3+ T cells 
infiltrating the lacrimal gland tissue and enhance the frequency of FoxP3+ T cells among 
infiltrating T cells. Ultimately, this experimental murine study provides one potential strategy for 
future anti-inflammatory therapies to focus on harnessing Tregs to restore the local 
immunological homeostasis within the ocular tissue.  
 116 
4.0  CONTROLLED RELEASE OF AN HDAC INHIBITOR FOR REDUCTION OF 
INFLAMMATION IN DRY EYE DISEASE 
This chapter is adapted from: Michelle L. Ratay, Stephen C. Balmert, Abhinav P. Acharya, 
Ashlee C. Greene, Thiagarajan Meyyappan, and Steven R. Little. (2017). (Submitted to 
Molecular Pharmaceutics) 
 
Specific Aim 3: To develop and evaluate local controlled release of an HDACi for the induction 
of Tregs.   
 
4.1 INTRODUCTION 
Several different acellular methods were explored to either recruit/induce Tregs in order to shift 
the ocular immunological microenvironment to promote homeostasis and subsequently prevent 
clinical features of DED. Although, these acellular approaches to recruit/bolster the overall pool 
of Tregs demonstrated promising results, there are several hurdles concerning the clinical 
translation of biologics like recombinant proteins (ex: CCL22, IL-2, TGF-β) (or even 
combinations of proteins/small molecule such as IL-2, TGF-β, and Rapamycin) as discussed in 
Chapters 2 and 3. Therefore, the development of formulations that can induce endogenous Tregs 
in vivo using one small molecule would drastically diminish concerns of clinical safety and 
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regulations. One particular potential class of drugs that could serve to simplify clinical 
translation is a class of small molecules known as histone deacetylase inhibitors (HDACi). 
Specifically, this particular class of small molecule drugs are known to induce differentiation and 
cell cycle arrest in cancer, and in particular an HDACi known as, SAHA(N-hydroxy-N′-phenyl-
octanediamide, Suberoylanilide hydroxamic acid), has been approved by the FDA for cutaneous 
T cell lymphoma (Commercially referred to as Zolinza®; Merck & Co., Inc., Whitehouse 
Station, NJ).[357] In addition to its usage as an anti-cancer therapeutic, this small molecule drug 
has been attracting interest as a potential anti-inflammatory therapeutic.[358] Moreover, HDACi 
have recently shown to enrich/enhance the local population of Tregs.[359] Specifically, the 
HDACi, SAHA, promotes Foxp3 acetylation, thereby increasing the binding of Foxp3 to DNA 
and enhancing suppressive functions of natural Tregs (nTregs) as shown in Figure 30.[360,361] 
Moreover, SAHA can also induce the generation of tolerogenic APCs via acetylation and 
activation of  STAT-3, which can then lead to differentiation of induced Tregs (iTregs) as shown 
in Figure 30.[362]  
Given that HDACi can both expand Tregs and enhance their immunosuppressive 
function, we hypothesized that using an HDACi (ex: SAHA) will effectively cause local 
induction of Tregs and prevent clinical symptoms associated with DED.  In order to test this 
hypothesis, SAHA was formulated into degradable microspheres made from a polymer with an 
excellent track record of prior FDA approval (poly (lactic-co-glycolic) acid). These microspheres 
are capable of sustainably releasing SAHA for several days. Local release of SAHA from these 
formulations in the lacrimal gland of mice prevent damage to the ocular tissue, enhance FoxP3 
mRNA expression in the lacrimal gland, and reduce the pro-inflammatory microenvironment 
observed in a model of murine DED. 
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Figure 30. A tolerogenic antigen presenting cell (APC) can activate a naïve T effector (Teff) and 
under the treatment of an HDACi this can lead to non-polarizing conditions resulting in the induction of 
Tregs and  can directly enhance the suppressive function of Tregs. 
 
 
 
4.2 MATERIALS AND METHODS 
In the following experiments, we aimed to assess the efficacy of SAHA microspheres for the 
prevention of pathological signs of DED. Moreover, we also aimed to determine whether the 
SAHA microspheres were able to reduce the pro-inflammatory ocular microenvironment.   
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4.2.1 Fabrication of HDACi Microspheres  
HDACi microspheres were fabricated using a single-emulsion evaporation technique due to the 
hydrophobic nature of SAHA. Specifically, 200 mg of Poly (lactic-co-glycolic) acid (PLGA-
65:35 lactide:glycolide, acid terminated) (MW:7,000-17,000) (viscosity: 0.16-0.24 dL/g, 0.1 % 
(w/v) (Sigma Aldrich, MO) and 40 mg of SAHA (Selleck Chem, TX) in 2.68 ml of 
dichloromethane and 1.32 ml of methanol then sonicated for 1 hour. Subsequently, this emulsion 
was then mixed with 60 ml of 2% polyvinyl-alcohol (PVA, MW ~25,000, 98% hydrolyzed; 
PolySciences) and homogenized (L4RT-A, Silverson, procured through Fisher Scientific) at 
3,500 rpm for 1 min. Subsequently, homogenized mixtures were added to 80 ml of 1% PVA on 
stir plate and left for approximately 1.5 hours in order for the organic solvent to evaporate. After 
1.5 hours, the microspheres were centrifuged (200 g, 5 min, 4 °C), washed 4 times with 
deionized water, and lyophilized for 48 hours (Virtis Benchtop K freeze dryer, Gardiner, NY).  
4.2.2 Characterization of HDACi Microspheres 
The morphology of the microspheres were characterized using scanning electron microscopy 
(SEM) (JEOL, JSM-6330F, Peabody, MA) and volume impedance measurements were 
performed on a Beckman Coulter Counter (Multisizer-3, Beckman Coulter, Fullerton, CA). In 
order to determine the release kinetics of the SAHA microspheres, 10 mg of the fabricated 
microspheres with drug (SAHA) or unloaded microspheres (composed of no drug only  polymer-
as a control) were added to 1ml of 0.2% Tween 80 in PBS (Sigma Aldrich, St. Louis, MO), 
which was placed onto a rotator at 37°C. The supernant was sampled daily and the release profile 
was determined using a NanoDrop 2000 Spectrophotometer (ThermoFisher Scientific, MA). 
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4.2.3 Mice 
Balb/c, female mice aged 6-8 weeks were utilized in this study. (Charles Rivers Laboratories, 
Wilmington, MA). All murine experiments were approved by the Institutional Animal Care and 
Use Committee, University of Pittsburgh, Pittsburgh, Pa.  
4.2.4 Murine Model 
10 mg/ml of Concanavalin A (ConA) (Sigma Aldrich, St. Louis, MO) in phosphate buffered 
saline solution (PBS) was injected into the lacrimal glands with a 28.5 gauge needle using a 
dissecting microscope in order to induce an inflammatory-murine model of DED. ( 10 mg/ml  of 
either Blank MS or SAHA MS were simultaneously administered at the same time as 
ConA).[222,337]  
4.2.5 Tear Production 
In order to measure tear production, phenol red cotton threads were utilized. (Oasis Medical, San 
Dimas, CA). Specifically, the phenol red thread was placed in the lateral canthus of the eye for a 
period of 60 seconds, and the amount of tears absorbed onto the thread (when tears are absorbed 
onto the thread a color change occurs from yellow to red) was measured using a dissecting 
microscope (Olympus SZX10, Waltham, MA).  
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4.2.6 Corneal Fluorescein Staining 
Approximately 1µl of fluorescein (1% solution in PBS) was applied to the conjunctival sac. 
Subsequently, the ocular surface was examined using a dissecting microscope (Olympus SZX10, 
Waltham, MA) to identify punctate staining. The scoring of staining was completed by a masked 
ophthalmologist, and scored 0 for no staining, score 1 for a quarter of staining, score of 2 for less 
than a half, score of 3 for half, and 4 for more than half of the eye.  
4.2.7 Ocular Histology 
At the end of the one-week study, murine eyes were exenterated and fixed in 10% neutral 
buffered formalin solution for a period of 48 hours.  Then paraffin embedded sections were cut at 
approximately 5µm and stained with Periodic Acid Schiff (PAS). These histological sections 
were scanned and the goblet cell density was quantified using a Zeiss Axio Scan. Z1 
(Thornwood, NY) and Pannoramic Viewer software (3D HISTECH Ltd.).  
4.2.8 qRT-PCR 
Total RNA was extracted from excised lacrimal glands using TRI-reagent (Molecular Research 
Center, Cincinnati, OH), and quantified using a NanoDrop 2000 (Thermo Scientific).  For the 
reverse transcriptase assay, 2 μg RNA was converted to cDNA using a QuantiTect Reverse 
Transcription Kit (Qiagen, Valencia, CA). Quantitative real-time PCR was then performed using 
VeriQuest Probe qPCR Mastermix (Affymetrix, Santa Clara, CA), (Thermo Scientific) specific 
for (IFN-γ:Mm01168134_m1, FAM-MGB dye), (IL-12: Mm01288989_m1, FAM-MGB dye), 
 122 
(IL-6:Mm00446190_ml, FAM-MGB dye),(FoxP3: Mm00475162_m1, FAM-MGB dye) and 
(Gusb: Mm01197698_m1, VIC-MGB PL dye, endogenous control).  Duplex reactions (target 
gene + GUSB) were run and analyzed on a StepOnePlus Real-Time PCR System (Applied 
Biosystems, Carlsbad, CA). Relative fold changes of IFN-γ, IL-12, IL-6, and FoxP3 expression 
were calculated and normalized based upon the  2-ΔΔCt method, with the Saline group as the 
untreated control.  
4.2.9 Suppression Assay 
Lymphocytes were isolated from Balb/c spleens and stained with antibodies against CD4, CD25, 
and CD45RB (eBioscience, San Diego, CA). Flow activated cell sorting (FACS) was performed 
(FACSAria, BD Bioscience) to obtain Teff (CD4+CD25-CD45RBhi) and Treg (CD4+CD25-
CD45RBlo). Teff and Treg were labeled with CellTrace CFSE or CellTrace Far Red, respectively 
(Invitrogen, Carlsbad, CA). Teff were cultured in round-bottom 96 well plates (5 x 104 
cells/well) with Dynabeads Mouse T-Activator CD3/CD28 (Gibco, Gaithersburg, MD) 
stimulation (1 Dynabead: 4 Teff) and 0:1, 1:1, 1:2, or 1:4 ratios of Treg:Teff. T cells were 
cultured in RPMI media (Corning, Corning, NY) containing either 0, 50, or 200 nM SAHA 
(Selleck Chem, Houston, Texas) for 72 hours. T cells were stained with Fixable Viability Dye 
(eBioscience, San Diego, CA) and CFSE dilution was analyzed by flow cytometry. 
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4.2.10 Statistical Analysis 
 
Data expressed as mean ± S.D.  Comparisons between multiple treatment groups were performed 
using one-way ANOVA, followed by Bonferroni multiple comparisons, and p ≤ 0.05 was 
considered statistically significant. For PCR data, a Grubb’s test was performed to determine any 
significant outliers. Any significant outlier identified  (p > 0.05) was excluded from the statistical 
analysis. If an assumption of the One-Way ANOVA was not met a non-parametric test was 
performed. Statistical tests were performed using GraphPad Prism Software 6.0 (GraphPad 
Prism, San Diego, CA). 
 
4.3 RESULTS  
4.3.1 Characterization of SAHA Microspheres 
Scanning electron micrographs (SEM) (Figure 31A) illustrate that individual, polymer particles 
are spherical with average diameter of  ~17 µm (Blank Microspheres) and  ~17 µm (SAHA 
Microspheres), which was confirmed with a Coulter Counter (representative plots of volume 
impedance measurements shown below in Figure 31B.  Additionally, the release kinetics were 
characterized using a NanoDrop (UV-vis spectrophotometer) through detection of the 
absorbance of SAHA, which demonstrates a cumulative release of approximately 50 ng/mg of 
microspheres over the course of 5-6 days shown in Figure 32. 
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Figure 31. Characterization of SAHA Microspheres. (A) Representative scanning electron 
microscopy (SEM) images (1000X) (B) Volume Impedance Measurements (Coulter Counter) of Blank 
Microspheres and SAHA Microspheres.  
Figure 32. Cumulative Release of SAHA Microspheres. 
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4.3.2 Aqueous Tear Production is Restored by SAHA Microsphere Treatment 
To determine whether SAHA MS were capable of preventing key signs of DED, aqueous tear 
secretion was examined using phenol red threads at the conclusion of the experimental study.[222] 
The lacrimal gland injection of ConA with or without Blank MS significantly reduced tear 
production, compared to saline (non-diseased) injected mice as shown in Figure 33.  Notably, 
the loss of tear production was prevented by the administration of SAHA MS as compared to the 
ConA (alone) group as shown below in Figure 33.  
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Figure 33. Tear Production is maintained with the administration of SAHA MS shown as mean ± S.D 
(n=4-5 per group) Saline (non-diseased), ConA (diseased), Blank MS ( diseased + unloaded microspheres), 
SAHA MS ( diseased + SAHA microspheres).  * p ≤ 0.05 
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4.3.3 The Administration of SAHA Microspheres Prevents Loss of Goblet Cell Density 
 Goblet cells are located within the stratified columnar conjunctival epithelial cells, and play an 
integral role in producing, mucin, a key component of tears.[363]  Moreover, goblet cells also 
produce MUC5AC, which acts as a gel layer to trap pollen and allergens.[301,364] A state of 
chronic inflammation (e.g. from DED) often results in depletion of these goblet cells, which in 
turn can lead to conjunctival epithelial squamous metaplasia and an abnormal tear film.[364] Thus, 
Periodic Acid Schiff (PAS) staining of the ocular tissue was used to determine whether SAHA 
MS could prevent the loss of goblet cells (pink/purple cells, Figure 34) in the conjunctiva, 
resulting from ConA-induced inflammation. Notably, there was a significant preservation of 
goblet cell density with the administration of SAHA MS as compared to the ConA alone group.  
Although, SAHA MS prevented some ConA-induced loss of goblet cells, there were still fewer 
goblet cells than in the non-diseased saline control as shown in Figure 34. 
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Figure 34. SAHA MS Preserve Goblet Cell Density in the Conjunctival Epithelial Layer.                  
(A) Quantification of  the Number of Goblet Cells per field shown as mean ± S.D (n=5-8 per group).              
(B) Representative Histological Images of the goblet cells in the conjunctiva (10X) of Saline (non-diseased), 
ConA (diseased), Blank MS ( diseased + unloaded microspheres), SAHA MS (diseased + SAHA 
microspheres)  * p ≤ 0.05 
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4.3.4 SAHA Microspheres Decrease Corneal Fluorescein Staining  
A hallmark of DED is an increase in permeability of the corneal epithelial layer of the ocular 
tissue.[342] Fluorescein staining, used to identify regions of the ocular surface damage, is a 
standard diagnostic measurement/indicator for dry eye disease severity.[342] Representative 
corneal fluorescein images were captured using a fluorescent dissecting microscope and scored 
by a masked ophthalmologist on a scale of 0 to 4, with 0 corresponding to no staining, and 4 
corresponding to staining on more than 50% of the cornea, as seen in Figure 35.  Compared to 
the ConA alone and ConA + Blank MS groups, uptake of fluorescein by the cornea was 
significantly lower in the Saline (non-diseased) and SAHA MS (preventative therapy) groups. 
Ultimately, the preventative therapy involving local administration of SAHA MS to lacrimal 
glands was able to reduce fluorescein scores by approximately 25% compared to mice with 
ConA-induced dry eye disease. 
 
 
 
 
 
 
 
 
 
 
 
 129 
 
 
 
 
 
Figure 35. Corneal Fluorescein Staining is Reduced with the Administration of SAHA MS.               
(A) Corneal Fluorescein Staining scored on a scale of (0-4) shown as mean ± S.D.  (n=6). (B) Representative 
Corneal Fluorescein Images of Saline (non-diseased), ConA (diseased), Blank MS (diseased + unloaded 
microspheres), SAHA MS (diseased + SAHA microspheres) * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001 
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4.3.5 mRNA Expression Altered in the Lacrimal Gland with SAHA Microspheres 
Inflammation in the lacrimal gland is associated with an infiltration of lymphocytes and an 
increase in pro-inflammatory cytokines.[309,365] Thus, mRNA expression levels were measured in 
the lacrimal gland tissue after ConA-induced inflammation. Data from qRT- PCR analyses 
indicate that IL-12, IFN-γ, and IL-6 induced by ConA (diseased control) were significantly 
reduced in the lacrimal glands of SAHA MS-treated as shown in Figure 36.[337] Additionally, the  
level of FoxP3 (Treg-specific transcription factor) mRNA expression was significantly higher in 
the lacrimal glands of  SAHA MS-treated mice, compared to the diseased (ConA) control shown 
in Figure 36.[366] Together, these data suggest that the SAHA MS were able to reduce the pro-
inflammatory microenvironment initiated by ConA and enhance the expression levels of FoxP3, 
reflecting either an increase in Treg number in the lacrimal gland, or greater FoxP3 expression 
by Tregs.  
 
 
 
 
 
 
 
 
 
 
 
 131 
 
 
 
 
 
Figure 36. mRNA Expression is Altered in the Lacrimal Gland Tissue with the administration of 
SAHA MS shown as mean ± S.D (n=4). * p ≤ 0.05 
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4.3.6 Lymphocyte Suppression Assay  
 
Various mechanisms by which SAHA can influence the Treg-Teff balance have been proposed 
including direct suppression of Teff proliferation and enhancement of Treg function.[358,359,367–
369]In order to gain insight into the mechanism of inflammation reduction in our model of murine 
DED, CFSE labeled Teff alone or CFSE labeled Teff co-cultured with Tregs were treated with 
SAHA and proliferation was assessed by CFSE dilution.  It was observed that Teff alone, treated 
with 200 nM SAHA, exhibited significantly reduced proliferation compared to Teff alone that 
were not treated with SAHA (Figure 7A).  Teff co-cultured with Tregs exhibited less 
proliferation, and this was further reduced in a dose-dependent manner by the addition of SAHA 
as shown in Figure 7B.  Although  200nM SAHA inhibited the proliferation of Teff alone by 
18% and a 1:1 Teff:Treg ratio (SAHA not treated) inhibited proliferation by 27%,  the 
combination of 200nM SAHA and  a 1:1 Treg:Teff ratio inhibited T cell proliferation by 66%. 
Overall, the impact of SAHA alone on solely T effector cells appears to be smaller compared to 
the co-culture of Tregs and Teff cells.         
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Figure 37. Lymphocyte Suppression Assay. (A) Representative Flow Cytometry Histograms of T 
effector cells only untreated (no SAHA) and cells treated with 50nM and 200nM SAHA and bar graphs 
shown as mean ± S.D. (B) Representative Flow Cytometry Histograms of 1:1 Treg: T effector cells untreated 
(no SAHA) and cells treated with 50nM and 200nM SAHA and bar graphs shown as mean ± S.D. * p ≤ 0.05;  
** p ≤ 0.01;  *** p ≤ 0.001 
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4.4 DISCUSSION 
Recently, immunosuppressive agents such as corticosteroids, such as cyclosporine (calcineurin 
inhibitor) or doxycycline (antibiotic) (as discussed in Chapter 1) have been investigated as a 
therapeutic to reduce inflammation associated with DED.36,37  However, long-term topical use of 
corticosteroids has been implicated in conditions such as glaucoma and retinopathy.38 As an 
alternative to non-specific corticosteroids and associated side effects, a histone deactylase 
inhibitor (HDACi) was utilized to alter the adaptive immune response to restore immunological 
homeostasis. Specifically, the HDACi, SAHA, was selected due to its ability to cause epigenetic 
modifications that regulate gene expression and protein function to modulate the function of 
immune cells such as T lymphocytes.18,19 In particular, SAHA and other HDACi can stimulate 
thymic production of anti-inflammatory Tregs, enhance Treg suppressive function, and promote 
the peripheral conversion of CD4+ naïve T cells into Tregs.19,35 Although, these HDACi have 
shown promising immunomodulatory effects on T lymphocytes, this class of small molecules 
possess a narrow therapeutic window (both efficacy and toxicity).39 Thus, being able to locally 
and sustainably deliver the HDACi would permit a much lower dosage and ultimately would 
reduce the amount of injections as compared to daily systemic administration for pre-clinical 
inflammatory models which can require 0.1 mg/kg/d.17 In this study, a controlled release system 
was fabricated to provide local administration of SAHA to the lacrimal gland in an inflammatory 
murine model of DED. These SAHA MS formulations maintained therapeutic levels over several 
days, ultimately reducing the total amount of HDACi required for therapeutic efficacy and 
minimizing toxicity concerns.17,40 
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SAHA releasing microspheres (MS) were fabricated using the biodegradable and 
biocompatible polymer poly (lactic-co-glycolic) acid (PLGA), and showed the ability to release 
SAHA over the course of approximately five days  (as shown in Figure 32) with the intention of 
altering the local microenvironment in the ocular tissue.[334,370] Notably, the data suggest that 
local administration of SAHA MS in the ocular tissue prevented several clinical signs of DED. 
For instance, a common clinical sign of DED is a reduction of overall tear production, which 
subsequently can lead to ocular dryness and irritation.[351]  While aqueous tear secretion was 
significantly reduced in diseased (ConA ± Blank MS), as expected,[222,329,337] SAHA MS 
treatment prevented ConA-induced loss of aqueous tear secretion  as  can be seen  in Figure 33. 
In addition to preserving aqueous tear production, effective therapeutics should also maintain the 
composition of tears by protecting gel-forming, mucin-producing goblet cells.[340] These goblet 
cells are located on the apical surface of the conjunctiva and produce important non-aqueous 
components of tears.[301,341] Interestingly, loss of goblet cells in ocular tissue in DED is 
reportedly due to an increase in the pro-inflammatory milieu.[301] Thus, in this study, histological 
sections of the conjunctiva were examined to determine whether SAHA MS treatment preserved 
mucin-producing goblet cells. Indeed, there was a significantly greater goblet cell density in 
SAHA MS-treated mice, compared to diseased (ConA) mice  as shown in Figure 34. Although, 
the preservation of goblet cell density was not as profound as other measurements (ex: corneal 
fluorescein staining) there was a statistically significant decrease in goblet cell numbers in the 
SAHA MS as compared to the ConA (diseased) group as can be seen in Figure 34. These results 
are in agreement with a previous report by DeZoeten et al., which demonstrated that 
administration of an HDACi from the same class as SAHA, led to preservation of intestinal 
goblet cells in an inflammatory colitis model.[371]  
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Since loss of aqueous tear production and/or mucin-producing goblet cells in DED 
ultimately leads to damage of the ocular surface,[372–374] it was investigated whether SAHA MS, 
which prevented both of these pathological features, also maintained integrity of the corneal 
epithelium. Corneal integrity was assessed with fluorescein,[342,375] a dye that stains dead 
epithelial cells and can diffuse into areas where cellular tight junctions are compromised.[354] 
Punctate staining was observed in mice with DED induced by ConA (with or without Blank 
MS), as shown in Figure 35. Notably, there was a 4-fold reduction in the average fluorescein 
staining score in the SAHA MS group, compared to ConA alone, suggesting that the HDACi was 
able to prevent damage to the ocular tissue initiated by ConA.  
In order to demonstrate that the prevention of clinical signs of DED was attributed to 
changes in the underlying T cell mediated immune response, the lacrimal gland 
microenvironment was evaluated using PCR analysis. The underlying pathogenesis of DED 
involves effector T cells that infiltrate the ocular tissue and secrete pro-inflammatory cytokines, 
which can directly affect the health of the ocular microenvironment.[304,305,376,377] Since increases 
in pro-inflammatory cytokines have been found in inflamed lacrimal gland tissues of mice, the 
microenvironment of the tissue was investigated to determine whether the SAHA MS-mediated 
prevention of clinical signs of DED was due to a reduced pro-inflammatory milieu in the ocular 
tissue.[352,378,379] Specifically, mRNA expression levels of pro-inflammatory cytokines (IL-12, 
IFN-γ, and IL-6) in lacrimal gland tissue were evaluated by qRT-PCR. Expression of IL-12 and 
IFN-γ was induced by ConA injection, relative to saline controls, as shown in Figure 36. This is 
likely attributed to ConA acting as a T-cell mitogen, ultimately leading to the production of Th1 
cytokines.[286,356]  Both of these findings in the ConA-induced murine model of DED are 
consistent with clinical reports that IL-12 and IFN-γ are upregulated in tears of patients with 
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DED.[351,363,378] In addition to increases in IL-12 and IFN-γ in the lacrimal gland, IL-6 was also 
significantly elevated by ConA, which is consistent with other reports of increased IL-6 
production in lacrimal glands of DED murine models.[273,337] Importantly, treatment with SAHA 
MS significantly inhibited ConA-induced expression of IL-12, IFN-γ, and IL-6  as shown in 
Figure 36. These reductions in the expression levels of pro-inflammatory cytokines prompted 
the question of whether SAHA MS were altering the immunological microenvironment by 
increasing anti-inflammatory Tregs. Previous studies have demonstrated that HDACi can expand 
FoxP3+ Tregs in vitro and in vivo.[359,367] Interestingly, we observed a significant increase in 
FoxP3 mRNA expression in the lacrimal gland tissue of SAHA MS-treated mice as shown in 
Figure 36, suggesting that the reduction of signs of DED and pro-inflammatory 
microenvironment in the lacrimal gland may be due to Tregs suppressing ocular inflammation. 
Future studies will be needed to determine whether increased FoxP3 expression in lacrimal 
glands of SAHA MS-treated mice is due to an increase in the number of Tregs in the tissue, or 
enhanced expression of FoxP3 by Tregs, which is associated with greater suppressive 
function.[380]  
In vitro experiments suggest, however, that SAHA may enhance Treg function in 
addition to directly inhibiting Teff  can be seen in Figure 37. Notably, neither Treg induction, 
nor increased expression of FoxP3 by Tregs was observed with SAHA treatment in vitro in our 
hands (data not shown). It is possible that this discrepancy between in vitro and in vivo results 
regarding FoxP3 expression is due to the fact that increased FoxP3 mRNA in the lacrimal gland 
may not necessarily correspond to increases in FoxP3 protein, as was measured in vitro 
experiments. Alternatively, enhanced FoxP3 expression in vivo could be due to the effects of 
dendritic cells (DCs) and other antigen-presenting cells on T cells in vivo.[358] In addition to 
 138 
direct effects on T cells, SAHA has also been shown to cause DCs to reduce costimulatory 
molecule expression and increase IDO production, both of which can promote Treg 
induction.[381] Due to the ubiquitous nature of histone acetylation and the dynamic nature of 
epigenetic regulation, it is not surprising that HDACi shift the Teff-Treg balance through 
multiple direct and indirect mechanisms. The results presented here are consistent with several 
previous reports of SAHA directly inhibiting Teff proliferation and enhancing the suppressive 
function of Tregs.[358,367,369,382]  
In summary, administration of SAHA MS preserved aqueous tear production and mucin-
producing goblet cells and prevented damage to ocular tissue by reducing the pro-inflammatory 
milieu in the lacrimal gland and enhancing numbers and/or function of FoxP3+ Tregs in an 
inflammatory murine model of DED. Given these encouraging results, future studies will be 
needed to fabricate SAHA MS with potentially longer release kinetics. Additionally, future 
studies will test the efficacy of SAHA MS in a larger pre-clinical rabbit model of DED, and 
potentially develop a novel topical formulation for ocular delivery for potential translation as a 
treatment for DED. Ultimately, the controlled delivery of SAHA may also have pharmacological 
benefits for other inflammation-based conditions (based on previous literature 
reports)[360,367,382,383] by locally inducing FoxP3+ Tregs and suppressing the pro-inflammatory 
milieu.    
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5.0  CONCLUSIONS AND FUTURE WORK 
The three aims presented in this thesis were to develop and utilize first-of-their-kind acellular 
systems that were designed to (1) recruit the body’s own endogenous Tregs, (2) induce the 
body’s own endogenous Tregs in situ or (3) induce/enhance the immunosuppressive function of 
the body’s own endogenous Tregs without the use of live cell therapy (without ex vivo expanded, 
live cells) for the prevention of DED. Particularly, this modulation in Treg function and 
prevalence in the lacrimal gland (in situ) possesses the ability to regulate the function of pro-
inflammatory cells, leading to re-establishment of immunological homeostasis in the ocular 
tissue and prevention of DED.  
In order to promote immunological homeostasis in the ocular tissue, and prevent the rapid 
diffusion of soluble drugs/biologics out of the lacrimal gland (reducing therapeutic efficacy as 
shown in Chapter 2), a local synthetically engineered sustained release system would be required 
to cause the recruitment/induction of Tregs to/at the site of inflammation to resolve destructive 
tissue damage. Moreover, local delivery is important, as it has been demonstrated that 
establishment of a concentration gradient is critical in order to direct lymphocytes to local sites 
of inflammation due to the short in vivo half-life of proteins.[290,384] Therefore, due to the 
advantages of a synthetically engineered sustained release system, formulations were fabricated 
using a biodegradable polymer, poly (lactic-co-glycolic) acid, in order to prevent the symptoms 
of DED in a murine model of ConA-induced DED.  
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Our data suggest that our Treg-based formulations were able to prevent clinical signs of 
DED. Specifically, Treg-recruiting microspheres were able to shift the ratio of Tregs to effector 
T cells in the lacrimal gland thereby preventing ocular tissue damage. In addition, to our strategy 
to recruit endogenous Tregs to the ocular tissue, we also examined bolstering the pool of Tregs 
by inducing peripheral naïve CD4+ T cells into Tregs. Notably, these formulations can induce 
naïve CD4+ T cells into Tregs through the sustained simultaneous presence of IL-2, TGF-β, and 
rapamycin (rapa) in the local ocular microenvironment.[334] However, when either the individual 
microsphere formulations alone (ex: Rapa, TGF-β, IL-2) or the combination of two microsphere 
formulations (ex: Rapa + TGF-β; Rapa + IL-2; TGF-β + IL-2) were administered, clinical signs 
of disease were not prevented. Therefore, the data suggests the combination of all three 
microspheres formulations (TRI MS) were required to shift the pro-inflammatory 
microenvironment and prevent clinical outcomes associated with DED pathogenesis. Although, 
TRI MS were effective in preventing clinical signs of disease, a more translational approach 
would be to utilize one small molecule as opposed to a combination of biologics/small molecule 
for the treatment of DED. 
     In an attempt to potentially enhance the clinical safety and reduce regulatory concerns 
surrounding the usage of biologicals and or the combination of biologicals/small molecules, a 
controlled release formulation of a clinically used small molecule was investigated as a potential 
treatment in a murine model of DED. Specifically, a class of histone deactylase inhibitors 
(HDACi-known as SAHA), was chosen due to its ability to increase the expression of FoxP3 in 
vivo and enhance the suppressive function of Tregs.[360] Therefore, a controlled release 
formulation of HDACi microspheres was developed encapsulating SAHA in order to  investigate 
whether this particular small molecule could prevent signs of DED and reduce the pro-
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inflammatory milieu in the lacrimal gland. Notably, SAHA MS were able to prevent clinical 
signs of DED, reduce the pro-inflammatory ocular microenvironment, and enhance FoxP3+ 
expression in the lacrimal gland tissue. Given these encouraging results, future work will be 
performed to examine the efficacy of these particular formulations in a pre-established model of 
DED in addition to the ConA model (preventative) utilized.   
Although, the ConA model was effective in studying the effects of these treatment on the 
downstream T-cells over a relatively short-period of time, the ConA-induced murine DED model 
does not intend to replicate the natural induction of DED in humans (i.e. desiccating stress 
induced tissue damage). Accordingly, future work will utilize a controlled environmental 
chamber (CEC-resembles the induction of DED in humans via desiccating stress) mouse model 
of DED to evaluate the efficacy of Treg-recruiting/inducing formulations. Using this model, it 
will become possible to determine whether these formulations can ultimately reduce the pro-
inflammatory microenvironment in the ocular tissue and improve the overall clinical symptoms 
of DED such as tear production, corneal lymphangiogenesis, goblet cell density, and corneal 
fluorescein staining. This model will also allow for the determination of the duration of effect 
(post administration) as well as optimizing administration for use in a therapeutic format.  
In addition to examining the efficacy of our  therapeutic formulations in a pre-established 
CEC model for future studies, we also plan on investigating the efficacy of these formulations in 
a larger animal model (more closely resembling the physiology and size of human eyes 
compared to mice) to facilitate translation. Specifically, a lapine DED model will be utilized to 
investigate the translatability of our Treg-based formulations (injected into the lacrimal gland) 
due to their large ocular surface (more similar to the size of a human eye compared to mice) as 
well as similarities in the composition of proteins in human and rabbit tears.[385–387]  Some of the 
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tests which will be performed utilizing the lapine model include: Shirmer test, corneal 
fluorescein staining, goblet cell density, and conjunctival impression cytology. We will also 
perform flow cytometry to determine the state of the immune homeostasis by analyzing T-cell 
populations of Th1 (CD4+IFN-γ+), Treg (CD4+Foxp3+), Tc1 (CD8+IFN-γ+) and antigen 
presenting cells (CD11c+MHCIIHiCD86Hi) populations in the lacrimal glands. The tear 
compositions of rabbits (with or without DED) will also be compared with the composition of 
human tears (with or without DED) to correlate key markers of DED to determine whether a 
decrease (in both humans and rabbits) in these key biomarkers markers (ex: relative levels of 
proteins such as IL-2, IL-4, IL-6, IFN-γ, IL-1β, TNF-α, MMP-9) are a sign of disease resolution. 
Furthermore, this model will afford us the ability to determine feasibility of additional routes of 
administration.[388]  
Although lacrimal gland injection itself could be possible from a translational 
perspective, (ex: superior temporal injection near the lacrimal gland or an inferior fornix 
injection near the eye subconjunctivally), a non-invasive, topical-based, long-acting eye drop 
formulation comprised of the Treg-inducing microsphere formulation and a thermo-responsive 
hydrogel could be a desirable alternative to lacrimal gland injection.[389] Moreover, this 
formulation can safely retain controlled release microspheres in the lower fornix of the eye, and 
has shown efficacy as a long term glaucoma drug delivery system and may be a potential future 
translational method of ocular delivery for DED.[389,390]  
Once the method of delivery (ex: topical gel, subconjunctival injection) is determined, 
pharmacokinetic studies on the distribution of these three factors (two cytokines and one small 
molecule) will be investigated for work focused upon optimization and translation of our 
treatment.  Specifically, this study will be performed in a larger, pre-clinical rabbit model (ocular 
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size more similar to humans). Additionally, since it is challenging to detect the relative small 
quantities (nanogram to picogram) of these three factors being released in the tissue (and 
delineate the between the endogenous cytokines (ex: IL-2 and TGF-β) and those released from 
the microspheres) new controlled release formulations will need to be developed that would 
include radio-labelled proteins. These radiolabeled drugs will also need to be tested to ensure 
similar loading and release profiles as the current microsphere formulations. Ultimately, in order 
to facilitate the translation of our formulations these dose dependent toxicity studies will be 
performed within an IND protocol (Investigational New Drug Application) enabling the ability 
to determine whether the small molecule/protein is reasonably safe for use in humans, and if it 
demonstrates pharmacological efficacy for commercialization.  
Finally, future testing and clinical evaluation of these controlled release formulations 
fabricated and utilized herein, could be repurposed for other ocular diseases involving 
inflammation (ex: AMD and Uveitis). Moreover, this engineered drug delivery system could 
serve as an easily modifiable platform to incorporate other types of biologics (ex: DNA) or small 
molecules with as little as picograms-to-nanograms of active agent for local delivery. Overall, 
the future translations of these new modern interdisciplinary engineered approaches are a novel 
therapeutic field, which aims to mimic the natural system of immuno-regulation, the human 
body. 
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APPENDIX A 
ONE –STEP SYNTHESIS OF FLUORESCENTLY LABELLED, SINGLE-WALLED 
CARBON NANOTUBES 
Michelle L. Guaragno, Riccardo Gottardi, Morgan V. Fedorchak, Abhijit Roy, Prashant N. 
Kumta and Steven R. Little. One-step synthesis of fluorescently labelled, single-walled carbon 
nanotubes. Chemical Communications. 2015, 51, 17233-17236. Reproduced by permission of 
The Royal Society of Chemistry.  
http://pubs.rsc.org/en/content/articlelanding/2015/cc/c5cc05573c#!divAbstract 
 
Single-walled carbon nanotubes (SWNTs) are a tubular allotrope of carbon whose hallmark is 
the sp2 hybridized structure.[391] Carbon nanotubes possess excellent mechanical, thermal and 
electrical properties, which have been widely studied for biomedical applications.[392–394] 
Specifically, SWNTs have been investigated for use in drug delivery, molecular sensing, and 
diagnostic imaging when conjugated to fluorophores, which can increase the aqueous solubility 
and endow the SWNTs with fluorescent properties.[395,396]  Currently, the procedures used to 
attach fluorophores involve either non-covalent interactions or the formation of a covalent bond. 
Non-covalent functionalization occurs via π-π interactions.[397] For instance, PEGylated 
fluorescein has been non-covalently attached to carbon nanotubes by simple sonication of the 
mixture, creating fluorescent SWNTs for imaging or pH sensing.[397] Alternatively, covalent 
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functionalization requires local alterations of the nanotube sidewalls and preferentially starts at 
the defect sites of the SWNT.[398] Covalent functionalization methods often exploit the 
hydrophilic carboxyl groups on carbon nanotubes, via several different esterification 
methods.[399] For example, carboxylic acids (COOH) can be converted to an acid chloride 
(COCl) through refluxing the carbon nanotubes in thionyl chloride (SOCl2), which is then 
reacted to covalently couple to a compound in order to form an ester.[400] Another method used to 
complete an esterification reaction of a fluorophore to a carbon nanotube includes a three-step 
process, which is necessary when the fluorophore of interest does not possess a primary reactive 
alcohol group.[401] The reaction begins by functionalizing the fluorophore with a compound 
containing an alcohol group followed by esterification to an acid chloride-functionalized carbon 
nanotube.[401]  
Yet to date, covalent functionalization of a fluorophore to a carbon nanotube via an 
esterification reaction has been achieved utilizing multiple-step syntheses. These decrease the 
overall weight yield and often require modification of the fluorophore in order to undergo an 
esterification reaction.[401] In fact, some fluorophores such as fluorescein do not possess a 
primary alcohol group. Therefore, the development of a new one-step esterification process to 
react the phenol group on a fluorophore and with the carboxylic acid on carbon nanotubes would 
be a desirable, straightforward approach to functionalize SWNTs with fluorophores with a 
potentially higher percentage weight yield. 
For this reason, we have developed a one-step reaction using boron trifluoride etherate to 
covalently attach the, fluorescein, to a carbon nanotube via a phenol group through an 
esterification reaction. This one-step synthetic process requires approximately 5 days due to the 
lower reactivity of the phenol, which is longer than other multi-step esterification 
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methods.[401,402] However; our one-step synthesis does not require modification of fluorescein. 
Our results suggest that the fluorescent characteristics are not affected and that the process has a 
95% overall weight yield. Effective functionalization and maintenance of the SWNT structure 
was confirmed using FT-IR, Raman, UV-vis-NIR and TGA. To our knowledge, this is the first 
description of a simple, one-step covalent esterification linkage to attach a fluorophore to a 
SWNT, with a corresponding high percentage weight yield.   
Single-walled carbon nanotubes (P3) (SWNT purified with nitric acid and contains 1.1 
atomic percentage of COOH groups, as assessed by Boehem titration were purchased from 
Carbon Solutions, Inc. (Riverside, CA).[403] The SWNTs were functionalized with fluorescein via 
an esterification reaction. Briefly, 50mg of (P3) SWNTs and 120mg of fluorescein free acid were 
mixed with 4ml of boron trifluoride etherate (≥46% BF3 basis), Sigma Aldrich (St. Louis, MO), 
which acts as a catalyst.  Nitrogen gas was bubbled for five minutes to degas the reaction. The 
reaction mixture was heated at 60°C in a silicone oil bath to maintain consistent heating and 
stirring for the duration. After five days, the reaction was cooled and transferred to a centrifuge 
tube. Then 10ml of diethyl ether etherate (Fisher Scientific, USA) was added to the reaction and 
centrifuged (Hettich Rotina 38/38R) at 23,760 G (11,000 rpm) for 10 minutes at 24°C. This 
served as a purification step to help ensure there was no remaining unreacted fluorescein. The 
centrifugation process was repeated until the supernatant was clear upon visual inspection. The 
remaining supernatant was then decanted and the product was dried in a desiccator for 24 hours 
at room temperature.   
 
 
 
 147 
 
 
 
Figure 38. The reaction scheme of the Single-Walled Carbon Nanotubes reacted with fluorescein in 
the presence of boron trifluoride etherate. The reaction starting materials are SWNT functionalized with 
carboxylic acid groups (1.1% atomic weight) and fluorescein free acid (green compound), which is reacted via 
esterification reaction using a Lewis acid catalyst (boron trifluoride etherate). 
 
 
 
 
 
 
 
The SWNT or functionalized SWNT were dispersed in deionized water (1mg/20ml) and 
bath sonicated (Branson 1510) for two hours. After sonication, the samples were transferred to a 
2ml quartz cuvette and scanned between 400nm and 1400nm with a UV-vis-NIR 
spectrophotometer (Varian Cary 5000).  This spectral range was chosen to include the maximum 
peak intensity for the fluorescein (496nm) and the distinct signatures of the S11 and M11 peaks 
of the carbon nanotubes.     
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Raman spectroscopy was completed using dried films of SWNT or functionalized carbon 
nanotubes. Suspensions of the SWNT and functionalized nanotubes were prepared as described 
above for UV-vis-NIR studies. Approximately 50μl of each suspension was pipetted onto a 
quartz microscope slide and dried at room temperature. Raman spectra were collected using a 
Raman microscope (Renishaw inVia) with a HeNe laser at excitation wavelength of 633nm. 
Samples were scanned between 100cm-1 and 3000cm-1 in order to examine the radial breathing 
mode (RBM), and the tangential modes (G and D band) intensities. The spectra were collected 
with a 10s exposure time and 20 scans were averaged for each sample. 
Approximately (1-2mg) of SWNTs were mixed with 100mg of KBr (Sigma, St. Louis, 
USA) and grinded using a mortar and pestle until all the nanotubes were evenly dispersed in the 
KBr and the resulting powder was formed into a pellet using a pellet press. The collection of the 
spectrum was completed between 500cm-1 and 3500cm-1 using a Nicolet IR200 FT-IR 
spectrometer.  
The Thermogravimetric analyses (TGA) of the carbon nanotubes were carried out in a 
STA 409 PC thermal analyzer (NETZSCH Instruments) under argon atmosphere employing a 
heating rate of 10°C min−1. 
The aforementioned techniques were employed in order to develop and characterize a 
new one-step synthetic process to attach a fluorophore moiety to a SWNT with a high weight 
percentage yield as shown in Figure 38. To that end, we employed a Lewis acid catalyst, 
enabling the nanotubes to remain in suspension throughout the reaction. SWNTs were 
functionalized with fluorescein via an esterification reaction using boron trifluoride etherate as a 
catalyst, and the product was isolated using centrifugation. Notably, this process results in a 95% 
overall weight percentage yield of the product. 
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Figure 39. FT-IR spectra of functional groups contained on the starting materials and reaction of 
SWNT and fluorescein  (A) (P3) SWNT starting material (B) SWNT mechanically ground with fluorescein as 
a physical mixture (1:4 ratio), and (C) the reaction product of SWNT and fluorescein (1:4 ratio) after 
esterification. 
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  The starting materials and the product were analysed via several approaches to 
determine functionalization and ensure that the structure of the nanotube was maintained. 
One method in particular, which was used to determine whether the fluorophore was 
indeed covalently conjugated to the carbon nanotube was FT-IR.  Figure 39 represents 
the spectra of 1) P3-SWNT  shown in Figure 39A), 2) a mixture of SWNT and 
fluorescein prior to their reaction as shown in Figure 39B and 3) the SWNT and 
fluorescein mixture after 5 days of reaction time represented in Figure 39C were obtained 
and compared. P3 SWNTs purchased through Carbon Solutions, Inc., have approximately 
1-3% lattice defects resulting in COOH groups on the nanotube surface. Each spectrum 
presented a broad peak at ~3400 cm-1, which is likely due to the O-H stretching modes of 
the bonds of the carboxylic acid group, while the peak in the 1600 cm-1 region likely 
corresponds to a carboxylic acid C=O stretching vibration.[404] The spectrum of the 
SWNT fluorescein mixture prior to the reaction as shown in Figure 39B has several 
additional peaks as compared to the spectra of SWNT alone shown in Figure 39A, which 
can be attributed to the bonds found in the free acid of fluorescein. After the 
functionalization reaction, a new sharp peak at ~1710 cm-1 appears in the fluorescein 
functionalized SWNT spectrum represented in Figure 39C, which represents evidence of 
the formation of an ester bond. The comparatively lesser intensity of the ester bond peak 
is dependent upon the percentage of available COOH groups on the P3 carbon nanotubes 
and the remaining carbonaceous impurities specifically the amorphous carbon, which 
results in a relatively lower theoretical level of possible functionalization.[405]  
 
 
 151 
 
 
 
Figure 40. Thermogravimetric Analysis (TGA) compares the stability of the (P3) SWNT (black) and 
the Reaction of SWNT and Fluorescein (green). The (P3) SWNTs have a higher thermal stability compared to 
the reaction of fluorescein SWNTs. The total weight loss difference between the SWNT and functionalized 
SWNT is 22%.   
 
 
 
 
We examined the characteristic weight loss of the SWNT compared to the fluorescein 
functionalized SWNT using TGA. The process of sidewall functionalization to the nanotubes can 
result in a lower thermal stability causing the functionalized SWNT to oxidize more rapidly than 
SWNT alone.[406,407] Over the 30°C to 900°C temperature range, the weight loss for SWNT was 
approximately 28% whereas for the fluorescein functionalized SWNT was nearly 50% as shown 
in Figure 40. Thus, the faster degradation rate concomitant with higher weight loss of 
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functionalized nanotubes further confirms that SWNT are functionalized with fluorescein. We 
assumed that the difference of weight loss in the TGA data was primarily due to the pyrolysis of 
the functionalized groups. Therefore, we estimated that approximately one fluorescein molecule 
for every 98 carbons atoms, equivalent to about 1.02%, was functionalized to the SWNT. This 
result, compared with the 1.1 atomic percentage of COOH groups per nanotube, suggests the 
conversion of ~92.7% of the carboxylic acid groups.[408,409]  
In order to assess the integrity of the SWNTs, we compared the spectra of unmodified 
SWNT and functionalized SWNT via Raman spectroscopy. This analysis suggested that the 
inherent structure of the SWNT was maintained through the functionalization process. Notably, 
multiple step processes can increase the probability of changes in the structure of the SWNTs, 
leading to the creation of Stone-Walls defects to the nanotubes sidewalls during reaction.[410] In 
Figure 41, the tangential modes (G and D bands at ~1590cm-1 and at ~1390cm-1, respectively) 
and the radial breathing mode (RBM) are clearly visible both in the SWNT (black line) and 
functionalized (green line) SWNT. Specifically, the presence of the RBM, typical of the thermal 
contractile nature of the nanotube, demonstrates the maintenance of the SWNT tubular 
structure.[411,412] Furthermore, the G/D band ratio does not show any noticeable significant 
increase after functionalization, from G/D=1.19 for SWNT and G/D= 1.20 for reaction of SWNT 
and fluorescein, suggesting that the reaction process did not increase the amount of sidewall 
defects.  
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 Figure 41. Raman spectrum examines the inherent structure and possible defects of (P3) SWNT 
(black) and reaction of SWNT and fluorescein (green). The 1590 cm-1 peak typical of the graphene band    
(G band) and the 1390 cm-1 peak typical of defect band (D band) are marked as well as the radial breathing 
mode (RBM) typical of thermal contractile nature of the nanotube, which is also highlighted in the insert. 
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After examining the functionalization and structure of SWNT, UV-vis-NIR spectroscopy 
was used to investigate the fluorescent properties of the functionalized nanotubes as shown in 
Figure 42. Comparisons were performed on the individual components (fluorescein and SWNT), 
their mixture, and their reaction product. The fluorescein free acid is characterized by a peak at 
λmax/496nm (red line), which is not affected by the presence of SWNT in the suspension (blue 
line). Chemical conjugation of SWNTs with fluorescein can also affect the spectrophotometric 
properties of the fluorescein molecule. Similarly, fluorescein absorption is only slightly red 
shifted after the reaction as shown in Figure 42, green line), which is not unexpected after 
conjugation through the C=O group.[413,414] We also investigated the physical structure of the 
nanotube, using UV-vis-NIR spectroscopy. The two characteristic peaks of SWNT are the M11 
metallic λmax/(600nm-800nm) and the S11 semiconducting λmax/(830nm-1200nm) peaks (black 
line).[415] The fluorescein functionalized SWNT spectra suggests that the inherent electronic 
structure (M11 and S11) of the nanotube is maintained after functionalization and exhibits a 
distinctive shift in the absorbance wavelength of fluorescein as shown in Figure 42 (green line).   
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Figure 42. UV-vis-NIR spectrum demonstrates the fluorescent properties of the (P3) SWNT (black), 
fluorescein (red), mixture of SWNT and fluorescein (1:4 ratio) (purple) and the reaction product of SWNT 
and fluorescein (green). The SWNT exhibit the signatures of the M11 (metallic) and S11 (semiconducting) 
bands. The fluorescein exhibits a peak corresponding to λ max/496nm. The reaction of SWNT and fluorescein 
produces the signature bands of nanotubes and a slight shift in the fluorescence of fluorescein. 
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Overall, the FT-IR and TGA data suggest that SWNT can be successfully functionalized 
with fluorescein using a one-step esterification reaction employing a Lewis acid catalyst. 
Furthermore, UV-vis-NIR and Raman spectroscopy demonstrate that the SWNT and the 
fluorescein structure were not significantly altered during the functionalization process. This 
process, notably, does require a five-day reaction period due to the low reactivity of the phenol 
and the carboxylic acid, compared to the shorter reaction time period of an esterification reaction 
using an acid chloride functionalized nanotube.[416] The reaction time is longer than other 
reactions of primary alcohol groups and could be potentially shortened by using a microwave 
reactor as reported with other SWNT reactions.[417] Also, the extent of functionalization on the 
nanotube could be enhanced by increasing the amount of carboxylic acid groups attached to the 
SWNT. This could potentially enhance the intensity of the fluorescence, enable additional 
fluorophores to be functionalized to the SWNT, or allow for attachment of another fluorophore 
moiety with similar chemical functionality. Lastly, the method described herein represents a one-
step, straightforward and potentially scalable process with a 95% overall weight yield that does 
not require any modification to the starting materials prior to initiating the reaction.   
   In conclusion, we have developed a new method to functionalize SWNTs with a 
commonly used fluorophore, fluorescein. The process occurs via a one-step esterification 
reaction under mild conditions, with no significant creation of defects to the structure of the 
nanotube. The esterification process enables a straightforward preparation, which can be further 
scaled and exploited for other biologically relevant fluorophores currently used as contrast agents 
for in vivo diagnostic imaging, pH sensors, and optical fluorescent imaging.[418–420] 
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